

1277153

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

January 24, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/527,615

FILING DATE: *December 05, 2003*

RELATED PCT APPLICATION NUMBER: PCT/US04/40844



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office



1364 U.S.PTO
120503

03/17 60/527615
U.S.PTO



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PROVISIONAL Patent Application of: Pradman Qasba et al.

Title: CATALYTIC DOMAINS OF BETA(1,4)-GALACTOSYLTRANSFERASE I HAVING ALTERED
METAL ION SPECIFICITY

Docket No.: 1662.027PRV

MAIL STOP PROVISIONAL APPLICATION

Assistant Commissioner for Patents

P.O. Box 1450
Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

- A PROVISIONAL Patent Application comprising:
 - Specification (69 pgs, including formal claim(s) 1 Statements of the Invention numbered 1 through 102 and a 1 page Abstract)
 - 11 Sheet(s) of drawing(s).
 - Signed Combined Declaration and Power of Attorney (pgs).
 - A check in the amount of \$160.00 to cover the Provisional Filing Fee.
- Provisional Application Cover Sheet (1 page).
- An executed Assignment to (pages), recordation cover sheet (1 page), and a check for the recordation fee of \$40.00.
- A verified statement to establish small entity status under 37 C.F.R. 1.9 and 1.27 (1 page).
- Communication Under 37 CFR 1.821 (1 pg.).
- Sequence Listing (9 pgs.)
- Sequence Listing in ASCII computer readable form.
- A return postcard.

Please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
Customer Number: 21186

By:
Monique M. Perdok
Reg. No. 42,989

"Express Mail" mailing label number: EV298564106US
Date of Deposit: December 5, 2003

This paper or fee is being deposited on the date indicated above with the United States Postal Service pursuant to 37 CFR 1.10, and is addressed to the Assistant Commissioner for Patents, Attn: MAIL STOP PROVISIONAL PATENT APPLICATION, P.O. Box 1450, Alexandria, VA 22313-1450.

(NEW FILING)

PROVISIONAL APPLICATION COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION under 37 C.F.R. 1.53 (c)

Docket Number	1662.027PRV	Type a plus sign (+) inside this box >	+
Customer No.	21186	Confirmation No.	

INVENTOR(s)/APPLICANT(s)

Name (last, first, middle initial)	RESIDENCE (CITY, AND EITHER STATE OR FOREIGN COUNTRY)
Qasba, Pradman Boeggeman, Elizabeth Ramakrishnan, Boopathy	Bethesda, MD Bethesda, MD, Frederick, MD

TITLE OF THE INVENTION (280 characters max)

CATALYTIC DOMAINS OF BETA(1,4)-GALACTOSYLTRANSFERASE I HAVING ALTERED METAL ION SPECIFICITY

CORRESPONDENCE ADDRESS

Schwegman, Lundberg, Woessner & Kluth
P. O. Box 2938
Minneapolis, Minnesota 55402

Attn: A. James Nelson

STATE	Minnesota	ZIP CODE	55402	COUNTRY	United States of America
-------	-----------	----------	-------	---------	--------------------------

ENCLOSED APPLICATION PARTS (check all that apply)

XXX	Specification	Number of Pages	69	Small Entity Statement	
XXX	Drawing(s)	Number of Sheets	11	XXX	Other (specify) Communication Under 37 CFR 1.821 (1pg); Sequence Listing(9 pgs); Sequence Listing in ASCII computer readable form

METHOD OF PAYMENT (check one)

XXX	A check or money order is enclosed to cover the Provisional filing fees	PROVISIONAL FILING FEE AMOUNT	\$160.00
XXX	The Commissioner is hereby authorized to charge any additional required fees or credit overpayment to Deposit Account Number: <u>19-0743</u>		

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.
No.

XXX Yes, the name of the U.S. Government agency and the Government contract number are: Department of Health and Human Services, N01-C0-12400

Respectfully submitted,

SIGNATURE Monique M. Perdok

Date December 5, 2003

TYPED OR PRINTED NAME Monique M. Perdok

REGISTRATION NO. 42,989

Additional inventors are being named on separately numbered sheets attached hereto.

PROVISIONAL APPLICATION FILING ONLY

**CATALYTIC DOMAINS OF BETA(1,4)-
GALACTOSYLTRANSFERASE I HAVING ALTERED METAL ION
SPECIFICITY**

5

Government Funding

The invention described herein was developed with support from the Department of Health and Human Services grant number N01-C0-12400. The U.S. Government may have certain rights in the invention.

10

Field of the Invention

The invention relates generally to β (1,4)-galactosyltransferase I mutants having altered metal ion specificity, and methods of use thereof. In addition, the invention relates to methods for using the β (1,4)-galactosyltransferase I mutants to increase the immunogenicity of an antigen, such as a vaccine, for synthesizing saccharide compositions, and for stabilizing platelets.

15

Background of the Invention

Oligosaccharides are chains composed of saccharide units, which are commonly known as sugars. Of the biological polymer families, oligosaccharides 20 are the least studied, due in part to the difficulty of sequencing and synthesizing their complex sugar chains. Currently, no generally applicable synthetic techniques for synthesizing oligosaccharides are available.

Intensive research efforts have been devoted to carbohydrates and molecules comprising carbohydrate fragments, such as glycolipids and glycoproteins. 25 Research interest in these moieties has been largely due to the recognition that interaction between proteins and carbohydrates are involved in a wide array of biological recognition events, including fertilization, molecular targeting, intracellular recognition, and viral, bacterial, and fungal pathogenesis. It is now widely appreciated that the oligosaccharide portions of glycoproteins and 30 glycolipids mediate cell-cell interactions, cell-ligand interactions, cell-extracellular matrix interactions, and cell-pathogen interactions.

It is thought that many of these interactions can be inhibited by oligosaccharides that have the same sugar sequence and stereochemistry found on the active portion of a glycoprotein or glycolipid involved in the interactions. The oligosaccharides are believed to compete with the glycoproteins and glycolipids for binding sites on the receptor proteins. For example, the disaccharide galactosyl- β (1,4)-N-acetylglucosamine is believed to be one component of the glycoprotein which interacts with receptors in the plasma membrane of liver cells. Thus, oligosaccharides and other saccharide compositions that mimic ligands recognized and bound by cellular receptors are thought to be useful in applications that include diagnostics and therapeutics.

In addition to mediating numerous cellular interactions, many oligosaccharides are recognized by the immune system. For example, Anti-Gal, a naturally occurring antibody present in all humans, specifically interacts with the carbohydrate epitope Gal- α (1-3)Gal- β (1-4)GlcNAc-R (α -galactosyl epitope). This antibody does not interact with any other known carbohydrate epitope produced by mammalian cells (Galili, *Springer Seminar Immunopathology*, 15:153 (1993)). Anti-Gal constitutes approximately 1% of circulating IgG (Galili et al., *J. Exp. Med.*, 160:1519 (1984)) and is also found in the form of IgA and IgM (Davine et al., *Kidney Int.*, 31:1132 (1987); Sandrin et al., *Proc. Natl. Acad. Sci.*, 90:11391 (1993)). It is produced by 1% of circulating B-lymphocytes (Galili et al., *Blood*, 82:2485 (1993)). Accordingly, the ability of carbohydrates to elicit an immune response can be utilized to increase the effectiveness of vaccines against many types of pathogens by linking such a carbohydrate to a vaccine to increase the immune response to the vaccine.

There has been relatively little effort to test oligosaccharides as therapeutic agents for humans or animal diseases however, as methods to synthesize oligosaccharides have been unavailable. Limited types of small oligosaccharides can be custom-synthesized by organic chemical methods, but the cost of such compounds is typically prohibitively high. In addition, it is very difficult to synthesize oligosaccharides stereospecifically and the addition of some sugars, such as sialic acid and fucose, has not been effectively accomplished because of the

extreme lability of their bonds. Improved, generally applicable methods for oligosaccharide synthesis are thereby desired for the production of large amounts of widely varying oligosaccharides for therapeutic purposes. Accordingly, the present invention provides enzymes and methods that can be used to promote the chemical linkage of numerous sugars that have previously been difficult to link.

Summary of the Invention

The invention provides altered β (1,4)-galactosyltransferase I catalytic domains that transfer galactose from a donor, UDP-galactose, to an acceptor, N-acetylglucosamine, to form a galactose- β (1,4)-N-acetylglucosamine bond in the presence of a wide range of metal ions. This broad metal utilization contrasts with that of the corresponding wild-type enzyme that utilizes manganese. The invention also provides β (1,4)-galactosyltransferase I catalytic domains that catalyze formation of glucose- β (1,4)-N-acetylglucosamine; N-acetylgalactosamine- β (1,4)-N-acetylglucosamine bonds; N-acetylgalactosamine- β (1,4)-glucose bonds; N-acetylglucosamine- β (1,4)-N-acetylglucosamine bonds; mannose- β (1,4)-N-acetylglucosamine bonds; and galactose- β (1,4)-N-acetylglucosamine-6-SO₃ bonds in the presence of a wide range of metal ions. The invention also provides polypeptides that contain each of the aforementioned catalytic domains.

The invention provides nucleic acid segments that encode the aforementioned β (1,4)-galactosyltransferase I catalytic domains. Expression cassettes and cells that include nucleic acid segments that encode the aforementioned β (1,4)-galactosyltransferase I catalytic domains are also provided.

Additionally provided are methods to synthesize a galactose- β (1,4)-N-acetylglucosamine moiety; a glucose- β (1,4)-N-acetylglucosamine moiety; an N-acetylgalactosamine- β (1,4)-N-acetylglucosamine moiety; an N-acetylgalactosamine- β (1,4)-glucose moiety; an N-acetylglucosamine- β (1,4)-N-acetylglucosamine moiety; a mannose- β (1,4)-N-acetylglucosamine moiety; and a galactose- β (1,4)-N-acetylglucosamine-6-SO₃ moiety in the presence of a wide range of metal ions.

The invention also provides methods to increase the immunogenicity of an antigen, and methods to prepare an oligosaccharide composition, including those having a defined sequence.

Further provided by the invention are oligosaccharides produced through use
5 of the catalytic domains and methods disclosed herein.

The invention also provides a method for stabilizing platelets.

Brief Description of the Figures

Figure 1A illustrates a metal ion activation curve of wild-type enzyme in the
10 presence of Mn²⁺ where the metal ion concentration is plotted on a log scale.

Figure 1B illustrates a metal ion activation curve of the M344E-Gal-T1 mutant enzyme in the presence of Mn²⁺ where the metal ion concentration is plotted on a log scale.

Figure 1C illustrates a metal ion activation curve of the M344H-Gal-T1
15 mutant enzyme in the presence of Mg²⁺ where the metal ion concentration is plotted on a log scale.

Figure 2A is a double-reciprocal plot for galactose transfer to GlcNAc catalyzed by C342T-Gal-T1. UDP-galactose concentrations are plotted as the variable substrate at the following fixed concentrations of GlcNAc: Solid circle, 2
20 mM; inverted open triangle, 3 mM; solid square, 5 mM; solid triangle, 20 mM.

Figure 2B is a double-reciprocal plot for galactose transfer to GlcNAc catalyzed by M344H-Gal-T1. UDP-galactose concentrations are plotted as the variable substrate at the following fixed concentrations of GlcNAc: Solid circle, 10 mM; inverted open triangle, 20 mM; solid square, 40 mM; solid triangle, 80 mM.

25 Figure 3A illustrates the overall crystal structure of the M344H-Gal-T1 mutant in the presence of UDP-Gal and Mg²⁺. The metal ion is shown as a sphere and the UDP-Gal molecule in ball-and-stick model.

Figure 3B is a stereo view of the final electron density maps contoured at
30 1.5 σ level around the UDP-Gal molecule and Mg²⁺ in the crystal structure of the M344H-Gal-T1•UDP-Gal •Mg²⁺ complex. Coordination of a magnesium ion is

shown to be similar to that of a manganese ion, which includes the sixth coordination with a water molecule.

Figure 4A is a stereo view of the binding of UDP-Gal•Mn²⁺ in the M344E-Gal-T1 mutant. The UDP-Gal and the mutant residues are shown in thick bonds.

5 W represents a water molecule.

Figure 4B is a stereo view showing binding of UDP-Gal•Mn²⁺ to the M344H-Gal-T1 mutant. The UDP-Gal and the mutant residues are shown in thick bonds. W represents a water molecule.

Figure 4C is a stereo view showing binding of UDP-Gal•Mg²⁺ to the
10 M344H-Gal-T1 mutant. The UDP-Gal and the mutant residues are shown in thick bonds. W represents a water molecule.

Figure 5 is an acceptor (GlcNAc) activation curve for the M344H-Gal-T1 mutant in the presence of either Mn²⁺ (closed circles) or Mg²⁺ (open inverted triangles) metal ion.

15 Figure 6 shows a comparison of the conformation of the long loop region of the open and closed structures of the wild-type β 4Gal-T1 (PDB: 1FGX, 1O0R). The electrostatic surface diagram of the portion of the enzyme molecule is shown except for the long loop residues 345 to 365. The negatively charged surface regions are indicated by light coloration (red in the original figure), while the
20 positively charged surface regions are indicated by darker coloration (blue in the original figure). The left-most tube (red in the original figure) corresponds to open conformation of the long loop, while the right-most tube (blue in the original figure) is to the closed conformation.

25 Detailed Description of the Invention

β (1,4)-galactosyltransferase I catalyzes the transfer of galactose from the donor, UDP-galactose, to an acceptor, N-acetylglucosamine, to form a galactose- β (1,4)-N-acetylglucosamine bond. This reaction allows galactose to be linked to an N-acetylglucosamine that may itself be linked to a variety of other molecules.

30 Examples of these molecules include other sugars and proteins. The reaction can be used to make many types of molecules having great biological significance. For

example, galactose- β (1,4)-N-acetylglucosamine linkages are important for many recognition events that control how cells interact with each other in the body, and how cells interact with pathogens. In addition, numerous other linkages of this type are also very important for cellular recognition and binding events as well as 5 cellular interactions with pathogens, such as viruses. Therefore, methods to synthesize these types of bonds have many applications in research and medicine to develop pharmaceutical agents and improved vaccines that can be used to treat disease.

The present invention is based on the surprising discovery that the metal 10 specificity of a β (1,4)-galactosyltransferase can be altered such that the enzyme can utilize magnesium as a cofactor during the catalytic process instead of manganese. This alteration allows the mutated enzyme to catalyze the transfer of a sugar from a donor to an acceptor through formation of a β (1,4) linkage in the presence of magnesium. Such enzymes are active under physiological conditions where 15 magnesium is present in sufficient concentration to allow the enzyme to function, and where manganese concentrations may not be adequate. Furthermore, such enzymes are useful during in vitro synthesis of β (1,4) linkages where magnesium is preferred over manganese. Such instances may exist when other magnesium utilizing enzymes are used during the synthetic process.

20 Enzymes having altered metal utilization may be mutated such that they can transfer many different types of donors to many different types of acceptors. Therefore, the mutated β (1,4)-galactosyltransferases of the invention can be used to synthesize a variety of products in the presence of magnesium, that until now, have been very difficult and expensive to produce.

25

Definitions:

Abbreviations: catalytic domain of β (1,4)-Galactosyltransferase I (CD β 4Gal-T1); β (1,4)-Galactosyltransferase I (β 4Gal-T1); catalytic domain (CD); wild-type (wt); galactosyltransferase activity (Gal-T); beta-mercaptoethanol (β -ME); N-acetylgalactosamine transferase activity (GalNAc-T); α -Lactalbumin (LA).

The term “acceptor” refers to a molecule or structure onto which a donor is actively linked through action of a catalytic domain of a galactosyltransferase, or mutant thereof. Examples of acceptors include, but are not limited to, carbohydrates, glycoproteins, and glycolipids.

5 The term “catalytic domain” refers to an amino acid segment which folds into a domain that is able to catalyze the linkage of a donor to an acceptor. For example, a catalytic domain may be from, but is not limited to, bovine β (1,4)-Galactosyltransferase I (Seq ID NO: 6), the catalytic domain from human β (1,4)-Galactosyltransferase I (Seq ID NO: 4), or the catalytic domain from mouse β (1,4)-

10 Galactosyltransferase I (Seq ID NO: 5). A catalytic domain may have an amino acid sequence found in a wild-type enzyme, or may have an amino acid sequence that is different from a wild-type sequence. For example, a catalytic domain may have an amino acid sequence that corresponds to amino acid residues 130-402 of SEQ ID NO: 6, except that the methionine is exchanged with histidine at amino acid

15 position 344.

The term “donor” refers to a molecule that is actively linked to an acceptor molecule through the action of a catalytic domain of a galactosyltransferase, or mutant thereof. A donor molecule can include a sugar, or a sugar derivative.

Examples of donors include, but are not limited to, UDP-galactose, UDP-mannose, UDP-N-acetylglucosamine, UDP-glucose, GDP-mannose, UDP-N-acetylgalactosamine, UDP-glucuronic acid, GDP-Fucose, and CMP-N-acetylneurameric acid. Donors include sugar derivatives that include active groups, such as cross-linking agents or labeling agents. Accordingly, oligosaccharides may be prepared according to the methods of the invention that include a sugar

20 derivative having a desired characteristic.

25 “Expression cassette” as used herein means a DNA sequence capable of directing expression of a particular nucleotide sequence in an appropriate host cell, comprising a promoter operably linked to the nucleotide sequence of interest that is operably linked to termination signals. It also typically comprises sequences required for proper translation of the nucleotide sequence. The expression cassette

30 may be one that is naturally occurring but has been obtained in a recombinant form

useful for heterologous expression. The expression of the nucleotide sequence in the expression cassette may be under the control of a constitutive promoter or of an inducible promoter that initiates transcription only when the host cell is exposed to some particular external stimulus. In the case of a multicellular organism, the

5 promoter can also be specific to a particular tissue or organ or stage of development.

The term "Magnesium" as used herein refers to divalent magnesium ion (Mg^{+2}). Magnesium can be derived from numerous magnesium salts. Examples of magnesium salts include magnesium chloride, magnesium acetate, magnesium nitrate, and the like.

10 The terms "Oligosaccharide" and "Polysaccharide" are used interchangeably herein. These terms refer to saccharide chains having two or more linked sugars. Oligosaccharides and polysaccharides may be homopolymers and heteropolymers having a random sugar sequence or a preselected sugar sequence. Additionally, oligosaccharides and polysaccharides may contain sugars that are normally found in
15 nature, derivatives of sugars, and mixed polymers thereof.

"Polypeptides" and "Proteins" are used interchangeably herein. Polypeptides and proteins can be expressed *in vivo* through use of prokaryotic or eukaryotic expression systems. Many such expressions systems are known in the art and are commercially available. (Clontech, Palo Alto, CA; Stratagene, La Jolla, CA). Examples of such systems include, but are not limited to, the T7-expression system in prokaryotes and the baculovirus expression system in eukaryotes.
20 Polypeptides can also be synthesized *in vitro*, e.g., by the solid phase peptide synthetic method or by *in vitro* transcription/translation systems. Such methods are described, for example, in U.S. Patent Nos. 5,595,887; 5,116,750; 5,168,049 and
25 5,053,133; Olson et al., Peptides, 9, 301, 307 (1988). The solid phase peptide synthetic method is an established and widely used method, which is described in the following references: Stewart et al., Solid Phase Peptide Synthesis, W. H. Freeman Co., San Francisco (1969); Merrifield, J. Am. Chem. Soc., 85 2149 (1963); Meienhofer in "Hormonal Proteins and Peptides," ed.; C.H. Li, Vol. 2 (Academic
30 Press, 1973), pp. 48-267; Bavaay and Merrifield, "The Peptides," eds. E. Gross and F. Meienhofer, Vol. 2 (Academic Press, 1980) pp. 3-285; and Clark-Lewis et al.,

Meth. Enzymol., 287, 233 (1997). These polypeptides can be further purified by fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on an anion-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; or ligand affinity chromatography.

The polypeptides of the invention include polypeptides having amino acid exchanges, i.e., variant polypeptides, so long as the polypeptide variant is biologically active. The variant polypeptides include the exchange of at least one amino acid residue in the polypeptide for another amino acid residue, including exchanges that utilize the D rather than L form, as well as other well known amino acid analogs, e.g., N-alkyl amino acids, lactic acid, and the like. These analogs include phosphoserine, phosphothreonine, phosphotyrosine, hydroxyproline, gamma-carboxyglutamate; hippuric acid, octahydroindole-2-carboxylic acid, statine, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, citruline, N-methyl-alanine, para-benzoyl-phenylalanine, phenylglycine, propargylglycine, sarcosine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, and other similar amino acids and imino acids and tert-butylglycine.

Conservative amino acid exchanges are preferred and include, for example; aspartic-glutamic as acidic amino acids; lysine/arginine/histidine as basic amino acids; leucine/isoleucine, methionine/valine, alanine/valine as hydrophobic amino acids; serine/glycine/alanine/threonine as hydrophilic amino acids. Conservative amino acid exchange also includes groupings based on side chains. Members in each group can be exchanged with another. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine. These may be exchanged with one another. A group of amino acids having aliphatic-hydroxyl side chains is serine and threonine. A group of amino acids having amide-containing side chains is asparagine and glutamine. A group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan. A group of amino acids having basic side chains is lysine, arginine, and histidine. A group of amino acids having sulfur-containing side chains is cysteine and methionine. For example, replacement of a leucine with an isoleucine or valine, an

aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid may be accomplished to produce a variant polypeptide of the invention.

5 I. β (1,4)-Galactosyltransferase I catalytic domains of the invention.

A. Catalytic domains that catalyze formation of a bond between a donor and an acceptor to form galactose- β (1,4)-N-acetylglucosamine bonds.

It has been discovered that the catalytic domain of a β (1,4)-Galactosyltransferase I can be altered such that the catalytic domain is able to utilize
10 a wide range of metal ions, including alkaline earth metals, which do not activate the wild-type enzyme during the catalytic β (1,4) linkage of galactose to N-acetylglucosamine. The ability to utilize a wide range of metal ions, instead of manganese as used by the wild-type enzyme, allows the catalytic domains of the invention to be used in conjunction with other synthetic methods used to produce
15 biological products. For example, polypeptides may be produced through use of in vitro transcription / translation protocols that utilize magnesium. A catalytic domain of the invention can then be added to the reaction mixture to glycosylate the polypeptide in the presence of magnesium. In addition, the catalytic domains and polypeptides of the invention can be added to blood or platelet preparations to
20 stabilize platelets so that they can be stored under chilled conditions (Hoffmeister et al., Science, 301:1531 (2003)).

In some embodiments, the catalytic domains of the invention have a methionine exchanged with another amino acid at an amino acid position corresponding to 344 in the bovine β (1,4)-galactosyltransferase I (SEQ ID NO: 6).
25 The corresponding methionine in the human and mouse β (1,4)-galactosyltransferase I is located at amino acid position 340 and 341 (SEQ ID Nos: 4 and 5 respectively). In mouse, human, and bovine β (1,4)-galactosyltransferase I, the methionine is located within the amino acid sequence CRMIRH (SEQ ID NO: 1). Accordingly, those of skill in the art can readily determine an equivalent amino acid in other
30 β (1,4)-galactosyltransferase I catalytic domains.

An example of a specific exchange is M344H. In the presence of Mg²⁺, the mutant, M344H-Gal-T1, exhibited 25% of the catalytic activity observed with the wild-type enzyme in the presence of Mn²⁺. It also has higher K_m for the substrates. The crystal structures of M344H-Gal-T1 in complex with either UDP-Gal•Mn²⁺ or 5 UDP-Gal•Mg²⁺, and the crystal structure of M344E-Gal-T1 in complex with UDP-Gal•Mn²⁺, have been determined at 2.3 Å resolutions. The structures show that the coordination stereochemistry of Mg²⁺ is quite similar to that of Mn²⁺. Both His344 and Glu344 in the mutants exhibit stronger coordination bonds with the metal ion compared to Met344 in the wild-type enzyme. This strong metal-ion coordination 10 in the mutants appears to reduce k_{cat} by interfering with the ability of the long flexible loop to undergo the required conformational changes during the catalytic cycle, but also by interfering with the formation of the transition state complex.

Catalytic domains and polypeptides of the invention in which amino acid residues involved with metal binding are mutated can optionally include an 15 additional mutation corresponding to amino acid position 342. Such a mutation may include exchange of cysteine at amino acid position 342 with threonine (C342T). However, other amino acids may be exchanged for cysteine that provide and active catalytic domain.

20 B. Catalytic domains that catalyze the formation of a bond between a donor and an acceptor to form glucose- β (1,4)-N-acetylglucosamine bonds.

Mutation of amino acid residues involved with metal binding can be combined with mutations in the donor binding site of β (1,4)-galactosyltransferase I that broaden the donor specificity of a catalytic domain or polypeptide of the 25 invention. More specifically, substitution of amino acid residues located in the donor binding site of β (1,4)-galactosyltransferase I to provide greater flexibility and decreased steric hindrance allow glucose to be bound and chemically bonded to N-acetylglucosamine. Such mutations provide for broadened donor binding, such as binding of glucose, while still preserving interaction with amino acid residues active 30 during catalytic bond formation between the donor and the acceptor. Without being bound by any theory, an example of a residue thought to be important for catalysis

is a glutamic acid positioned at amino acid position 317 (E317) in the bovine β (1,4)-galactosyltransferase I. This glutamic acid in bovine β (1,4)-galactosyltransferase I corresponds to a glutamic acid residue at amino acid position 313 and at amino acid position 314 in the human and mouse β (1,4)-galactosyltransferase I respectively.

5 Accordingly, the invention provides β (1,4)-galactosyltransferase I mutants having amino acid substitutions, insertions, and deletions that provide greater flexibility and decreased steric hindrance in the donor binding site to allow the mutated β (1,4)-galactosyltransferase I to catalyze chemical bonding of the donor to an acceptor, such as N-acetylglucosamine or glucose.

10 In some embodiments, the catalytic domains of the invention have an amino acid at position 344 exchanged for another amino acid, and arginine exchanged with another amino acid at an amino acid position corresponding to 228 in the bovine β (1,4)-galactosyltransferase I (SEQ ID NO: 6). An example of a specific exchange is R228K. The corresponding arginine in the human and mouse β (1,4)-galactosyltransferase I is located at amino acid position 224 and 225 (SEQ ID Nos: 4 and 5 respectively). In mouse, human, and bovine β (1,4)-galactosyltransferase I, the arginine is located within the amino acid sequence FNRAKLL (SEQ ID NO: 2). Accordingly, those of skill in the art can readily determine an equivalent amino acid in other β (1,4)-galactosyltransferase I catalytic domains.

15 20 In other embodiments, the catalytic domains of the invention have an arginine exchanged with another amino acid at an amino acid position corresponding to 228, and an alanine exchanged with another amino acid at an amino acid position corresponding to 229 in the bovine β (1,4)-galactosyltransferase I.

25 Such catalytic domains are exemplified by a catalytic domain of bovine β (1,4)-galactosyltransferase I having the arginine at amino acid position 228 exchanged with lysine (R228K), and the alanine at amino acid position 229 exchanged with glycine (A229G). The corresponding alanine in the human and mouse β (1,4)-galactosyltransferase I is located at amino acid position 225 and 226 (SEQ ID Nos: 4 and 5 respectively). In mouse, human, and bovine β (1,4)-galactosyltransferase I, the arginine is located within the amino acid sequence

FNRAKLL (SEQ ID NO: 2). Accordingly, those of skill in the art can readily determine an equivalent amino acid in other β (1,4)-galactosyltransferase I catalytic domains.

Catalytic domains and polypeptides of the invention in which amino acid residues involved with metal binding and donor binding are mutated can optionally include an additional mutation corresponding to amino acid position 342. Such a mutation may include exchange of cysteine at amino acid position 342 with threonine (C342T). However, other amino acids may be exchanged for cysteine that provide an active catalytic domain.

10

C. Catalytic domains that catalyze the formation of a bond between a donor and an acceptor to form N-acetylgalactosamine- β (1,4)-N-acetylglucosamine bonds.

Mutations that broaden the metal ion specificity of a catalytic domain or polypeptide of the invention can also be combined with mutations that alter donor specificity.

For example, it was postulated that formation of a hydrogen bond between N-acetylgalactosamine and an amino acid residue adjoining the donor binding site in β (1,4)-galactosyltransferase I is responsible for poor transfer of N-acetylgalactosamine to an acceptor. It was also postulated that mutation of one or more amino acid residues in the donor binding site in β (1,4)-galactosyltransferase I to eliminate hydrogen bond formation with N-acetylgalactosamine allows the mutated β (1,4)-galactosyltransferase I to transfer N-acetylgalactosamine from a donor to an acceptor more efficiently. Therefore, the invention includes mutants of β (1,4)-galactosyltransferase I in which the metal ion specificity is altered, and in which hydrogen bonds that reduce transfer of N-acetylgalactosamine to an acceptor, such as N-acetylglucosamine or glucose, are reduced or absent.

In some embodiments, the catalytic domains of the invention have an amino acid substitution at amino acid position 344, and also have a tyrosine exchanged with another amino acid at an amino acid position corresponding to 289 in the bovine β (1,4)-galactosyltransferase I (SEQ ID NO: 6). Examples of specific

exchanges are Y289L, Y289I, and Y289N. The corresponding tyrosine in the human and mouse β (1,4)-galactosyltransferase I is located at amino acid position 285 and 286 (SEQ ID Nos: 4 and 5 respectively). In mouse, human, and bovine β (1,4)-galactosyltransferase I, the tyrosine is located within the amino acid sequence 5 YVQYFGG (SEQ ID NO: 3). Accordingly, those of skill in the art can readily determine equivalent amino acids in other β (1,4)-galactosyltransferase I catalytic domains.

Mutants in which the tyrosine corresponding to that located at amino acid position 289 in the bovine β (1,4)-galactosyltransferase I has been exchanged by 10 another amino acid may optionally include an additional mutation corresponding to amino acid position 342. Such a mutation may include exchange of cysteine at amino acid position 342 with threonine (C342T). However, other amino acids may be exchanged for cysteine that provide an active catalytic domain.

15 D. Catalytic domains that catalyze the formation of a bond between a donor and an acceptor to form N-acetylgalactosamine– β (1,4)-glucose bonds.

β (1,4)-galactosyltransferase I catalytic domains and polypeptides of the invention, as described herein, that are able to catalyze chemical bond formation of N-acetylgalactosamine to an acceptor may be used in conjunction with α -lactalbumin to catalyze the formation of N-acetylgalactosamine– β (1,4)-glucose bonds. 20

α -Lactalbumin is a mammary gland-specific calcium-binding protein that alters the sugar acceptor specificity of β (1,4)-galactosyltransferase I toward glucose. Consequently, α -lactalbumin may be used to alter the acceptor specificity β (1,4)-galactosyltransferase I, and mutants thereof that are described herein, to efficiently catalyze N-acetylgalactosamine– β (1,4)-glucose bond formation. Conditions for use 25 of α -lactalbumin in conjunction with a galactosyltransferase, or active domain thereof, have been described (Ramakrishnan et al., J. Biol. Chem., 276:37665 (2001)).

E. Catalytic domains that catalyze the formation of a bond between a donor and an acceptor to form N-acetylglucosamine- β (1,4)-N-acetylglucosamine bonds, oligo N-acetylgalactosamine- β (1,4)-N-acetylglucosamine, and mannose- β (1,4)-N-acetylglucosamine.

5 The invention provides additional catalytic domains and polypeptides having mutations that broaden the metal ion specificity, and mutations that alter donor specificity.

For example, a catalytic domain obtained from bovine β (1,4)-galactosyltransferase I having exchanges at amino acid positions 228 (R228K) and 10 289 (Y289L) was able to catalyze the linkage of N-acetylglucosamine to N-acetylglucosamine to form a N-acetylglucosamine- β (1,4)-N-acetylglucosamine bond. The same mutant catalytic domain was able to catalyze the linkage of N-acetylgalactosamine to N-acetylglucosamine to form oligo N-acetylgalactosamine- β (1,4)-N-acetylglucosamine. The broadened donor specificity was further 15 demonstrated by the ability of the mutant catalytic domain to catalyze the linkage of mannose to N-acetylglucosamine to form mannose- β (1,4)-N-acetylglucosamine. Accordingly, numerous mutant catalytic domains having altered donor specificity may be created by mutating amino acids corresponding to those at positions corresponding to 228 and 289 of the bovine β (1,4)-galactosyltransferase I. As 20 described above, these amino acid positions may be readily determined in galactosyltransferase enzymes obtained from other organisms, such as humans, and mutated to produce additional catalytic domains having altered donor specificity. These amino acid mutations that alter donor specificity can be combined with 25 mutations that broaden metal ion specificity, such as mutation of an amino acid corresponding to the methionine at amino acid position 344 in the bovine β (1,4)-galactosyltransferase I.

These catalytic domains and polypeptides of the invention can optionally include an additional mutation corresponding to amino acid position 342. Such a mutation may include exchange of cysteine at amino acid position 342 with 30 threonine (C342T). However, other amino acids may be exchanged for cysteine that provide an active catalytic domain.

F. Catalytic domains that catalyze the formation of a bond between a donor and an acceptor having a bulky side-group to form for example, galactose- β (1,4)-N-acetylglucosamine-6-SO₃ bonds.

The invention provides additional catalytic domains and polypeptides having 5 mutations that broaden the metal ion specificity, and mutations that alter acceptor specificity.

The metal ion specificity, and acceptor specificity of a catalytic domain obtained from a galactosyltransferase may be altered to create catalytic domains capable of transferring a donor onto an acceptor having a bulky and/or charged side-10 group in the presence of a broad range of metal ions.

An example of such an altered catalytic domain obtained from bovine β (1,4)-galactosyltransferase I has substitutions at amino acid positions 279 (K279S) and 280 (F280T). This altered catalytic domain is able to catalyze the transfer of galactose to N-acetylglucosamine-6-SO₃ to form galactose- β (1,4)-N-15 acetylglucosamine-6-SO₃. Additional catalytic domains may be created by altering one or more amino acid residues at positions corresponding to 279 and 280 of the bovine β (1,4)-galactosyltransferase I. As described above, these amino acid positions may be readily determined in galactosyltransferase enzymes obtained from other organisms, such as humans, and mutated to produce additional catalytic 20 domains having altered acceptor specificity. These catalytic domains may be further altered to include additional amino acid exchanges that broaden the metal ion specificity of the catalytic domain.

The amino acids at positions corresponding to 279 and 280 in the bovine β (1,4)-galactosyltransferase I may be exchanged individually or together to create 25 many different catalytic domains having altered acceptor sites able to accept numerous acceptors having bulky (sterically large) or charged side-groups. Such altered catalytic domains may be used to catalyze linkage of sugars from a donor to an acceptor having a desired side-chain.

These catalytic domains and polypeptides of the invention can optionally 30 include an additional mutation corresponding to amino acid position 342. Such a mutation may include exchange of cysteine at amino acid position 342 with

threonine (C342T). However, other amino acids may be exchanged for cysteine that provide an active catalytic domain.

II. Catalytic domains of the invention may be included within full-length

5 β (1,4)-galactosyltransferase I enzymes, or in recombinant molecules containing the catalytic domains.

Peptides of the invention include isolated catalytic domains, full-length β (1,4)-galactosyltransferase I enzymes containing a catalytic domain of the invention, as well as recombinant polypeptides comprising a catalytic domain of the 10 invention that are linked to additional amino acids. Such polypeptides may be expressed from DNA constructs and expression cassettes that are produced through use of recombinant methods. Such methods have been described. Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (2001).

15 Galactosyltransferase enzymes containing a catalytic domain of the invention may be produced in soluble form. Methods that may be used to produce such soluble enzymes have been described (U.S. Patent No. 5,032,519). Briefly, a hydrophobic transmembrane anchor region of a galactosyltransferase is removed to produce an enzyme that is in soluble form.

20 Alternatively, β (1,4)-galactosyltransferase enzymes containing a catalytic domain of the invention may be produced such that they are anchored in the membrane of a cell that expresses the galactosyltransferase. Such enzymes may be produced that are anchored in the membranes of prokaryotic and eukaryotic cells. Methods to produce such enzymes have been described (U.S. Patent No: 6,284,493).

25 Briefly, in the case of prokaryotes, the signal and transmembrane sequences of the galactosyltransferase are replaced by a bacterial signal sequence, capable of effecting localization of the fusion protein to the outer membrane. Suitable signal sequences include, but are not limited to those from the major E.coli lipoprotein Lpp and lam B. In addition, membrane spanning regions from Omp A, Omp C, Omp F 30 or Pho E can be used in a tripartite fusion protein to direct proper insertion of the fusion protein into the outer membrane. Any prokaryotic cells can be used in

accordance with the present invention including but not limited to *E. coli*, *Bacillus* sp., and *Pseudomonas* sp. as representative examples.

In another embodiment, the native transmembrane domain of the galactosyltransferase is replaced by the transmembrane domain of a bacterial outer membrane protein. In this embodiment, the galactosyltransferase signal sequence and the bacterial transmembrane region act in concert to anchor the galactosyltransferase to the bacterial outer cell membrane. Nearly any outer membrane bound protein is suitable for this use including but not limited to Omp A, Omp C, and Omp F, Lpp, and Lam B. The catalytic portion of the galactosyltransferase should be fused to an extracellular loop in the bacterial transmembrane region in order to insure proper orientation of the fusion protein on the outer membrane surface and not in the cytoplasm or periplasm of the cell. Insertion of a protein into such a loop region has been previously reported (Charbit et al., *J. Bacteriology*, 173:262 (1991); Francisco et al., *Proc. Natl. Acad. Sci.*, 89:2713(1992)).

The present invention is also applicable for use with eukaryotic cells resulting in cell surface expression of galactosyltransferases in known culturable eucaryotic cells including but not limited to yeast cells, insect cells, chinese hamster ovary cells (CHO cells), mouse L cells, mouse A9 cells, baby hamster kidney cells, C127 cells, COS cells, Sf9 cells, and PC8 cells.

In another embodiment of the present invention, the transmembrane domain of the galactosyltransferase is replaced by the transmembrane domain of a plasma membrane protein. The transmembrane domain of any resident plasma membrane protein will be appropriate for this purpose. The transmembrane portions of the M6 P/IGF-II receptor, LDL receptor or the transferrin receptor are representative examples.

In another embodiment the Golgi retention signal of the galactosyltransferase is disrupted by site-directed mutagenesis. This approach mutates the amino acids responsible for localizing the galactosyltransferase to the Golgi compartment. The resultant galactosyltransferase is transported to the plasma membrane where it becomes anchored via its modified transmembrane sequences.

Substitution of isoleucine residues for the native amino acids in the transmembrane region of the β (1,4)galactosyltransferase has been shown to preferentially localize the enzyme to the plasma membrane instead of the Golgi apparatus (Masibay et al., *J. Biol. Chem.*, **268**:9908 (1993)).

5

III. A stem region that promotes the *in vitro* folding of a catalytic domain of a galactosyltransferase.

β (1,4)-galactosyltransferase I is a type II Golgi resident protein with a short cytoplasmic tail, a transmembrane domain followed by a stem region and has a 10 globular catalytic domain that faces the Golgi lumen. When a catalytic domain of β (1,4)-galactosyltransferase I is expressed in *E. coli*, it forms insoluble inclusion bodies. These inclusion bodies can be collected and then solubilized and folded *in vitro* to produce catalytically active domains. Thus, the *in vitro* folding efficiency is directly related to the quantity of active enzyme that is produced from the isolated 15 inclusion bodies. Accordingly, methods to increase the *in vitro* folding efficiency would provide increased production of catalytic domains that can be used to create useful products.

The invention provides materials and methods that improve *in vitro* folding of catalytic domains from galactosyltransferases that are related to the use of a stem 20 region (for example, SEQ ID NOs: 7 and 8) of β (1,4)-galactosyltransferase I. It is thought that fusion of a stem region from a β (1,4)-galactosyltransferase I to the amino-terminus of a catalytic domain of a β (1,4)-galactosyltransferase I produces increased *in vitro* folding efficiency of the catalytic domain. This increase in folding is thought to be universal among β (1,4)-galactosyltransferase I enzymes and 25 was demonstrated with both the bovine and human enzymes.

It is further thought that inclusion of PEG-4000 and L-Arg in the folding reaction will result in a four-fold to seven-fold increase in catalytic domains having altered metal ion specificity that are natively folded when compared to refolding of the catalytic domain alone in the absence of PEG-4000 and L-Arg. PEG-4000 and 30 L-arginine are thought to beneficially affect the solubility of folding intermediates of both catalytic domain-proteins (CD-proteins) and stem region/catalytic domain

proteins (SRCD-proteins) during *in vitro* folding or protein obtained from inclusion bodies. It is thought that the SR-domain, like PEG-4000 and L-arginine, helps to solubilize the folding intermediates, and hence enhanced the formation of both native and misfolded-SRCD molecules. The presence of PEG-4000 and L-arginine
5 enhanced the solubilization of the folding intermediates of SRCD-molecules even further. The misfolded SRCD proteins, in contrast to the majority of CD-proteins, remained soluble even in the absence of PEG-4000 and L-arginine. Therefore, the misfolded SRCD-proteins were not removed as precipitates during dialysis.
Misfolded SRCD-proteins can be separated from properly folded proteins through
10 binding on UDP-agarose columns. Thus the SR-domain is thought to act as a solubilizing agent both for the misfolded and folded catalytic domain. It is thought that the increased solubility of SRCD-proteins is produced by preventing aggregation of misfolded proteins. In this respect its mode of action is thought to resemble the action of chaperone proteins. The positive effect of the *N*-terminal
15 stem region in the folding and stability of the native protein is very useful for producing large quantities of other galactosyltransferase family members.

The *in vitro* folding efficiency of bovine β (1,4)-galactosyltransferase I was further increased by substituting the cysteine at amino acid position 342 with a threonine (C342T). Analogous mutations can be made in β (1,4)-
20 galactosyltransferase I enzymes from other organisms.

It has been determined that the wild-type bovine SRCD β 4Gal-T1, folded and purified from inclusion bodies, was cleaved at Ser96 within the stem region over a short period of time. Therefore, to decrease degradation of bovine SRCD β 4Gal-T1, the serine at amino acid position 96 can be exchanged with an Ala
25 to produce S96A-SRCD β 4Gal-T1. After folding and purification from bacterial inclusion bodies, S96A-SRCD β 4Gal-T1 was found to be more stable over a long period of time when compared to SRCD β 4Gal-T1, which did not include the S96A mutation.

Accordingly, the invention includes stem regions from members of the
30 galactosyltransferase family that can be fused to a catalytic domain of a galactosyltransferase to provide increased *in vitro* folding of the catalytic domain.

Such stem regions can be readily determined based on amino acid sequence homology to the bovine stem region and tested for the ability to promote folding of a galactosyltransferase catalytic domain. The invention also includes the mutants disclosed herein and their corresponding analogs in other species.

5 General methods for isolating and folding inclusion bodies containing galactosyltransferase catalytic domains have been previously described (Ramakrishnan et al., *J. Biol. Chem.*, 276:37665 (2001)). These methods may be used in conjunction with the stem region of the invention, PEG-4000, and L-Arg to increase the folding efficiency of a galactosyltransferase catalytic domain. These
10 methods are described in the examples section herein.

IV. Nucleic acid segments encoding catalytic domains of β (1,4)-galactosyltransferase I, expression cassettes that include the nucleic acid segments, and cells that include the nucleic acid segments and expression cassettes.

15 The present invention provides isolated nucleic acid segments that encode catalytic domains of β (1,4)-galactosyltransferase I having altered metal ion, donor, or acceptor specificity. The present invention also provides nucleic acid segments that encode amino acid segments that promote proper folding of catalytic domains from galactosyltransferases, such as β (1,4)-galactosyltransferase I.
20 Nucleic acid sequences encoding human β (1,4)-galactosyltransferase I (SEQ ID NO: 8), as well as other β (1,4)-galactosyltransferases I from other organisms are available. These nucleic acid sequences can be modified to encode the catalytic domains and amino acid segments of the invention through use of well-known techniques (Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 3rd edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (2001)). For example, a portion of the nucleic acid sequence encoding human β (1,4)-galactosyltransferase I (SEQ ID NO: 11) can be inserted into an expression vector such that an amino acid segment corresponding to the catalytic domain of human β (1,4)-galactosyltransferase I (SEQ ID NO: 9) is expressed upon transformation of a cell
25 with the expression vector. In another example, bovine β (1,4)-galactosyltransferase I can be altered to exchange the methionine at amino acid position 344 with
30

histidine through use of site-directed mutagenesis. Similar methods may be used to produce nucleic acid segments encoding additional mutants, catalytic domains, and polypeptides described herein.

The nucleic acid segments of the invention may be optimized for expression
5 in select cells. Codon optimization tables are available. Harlow and Lane,
Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1988.

The nucleic acid segments can be inserted into numerous types of vectors. A vector may include, but is not limited to, any plasmid, phagemid, F-factor, virus, cosmid, or phage in double or single stranded linear or circular form which may or
10 may not be self transmissible or mobilizable. The vector can also transform a prokaryotic or eukaryotic host either by integration into the cellular genome or exist extrachromosomally (e.g. autonomous replicating plasmid with an origin of replication).

Preferably the nucleic acid segment in the vector is under the control of, and
15 operably linked to, an appropriate promoter or other regulatory elements for transcription *in vitro* or in a host cell such as a eukaryotic cell or microbe, e.g. bacteria. The vector may be a bi-functional expression vector which functions in multiple hosts. In the case of genomic DNA, this may contain its own promoter or other regulatory elements and in the case of cDNA this may be under the control of
20 a promoter or other regulatory sequences for expression in a host cell.

Specifically included are shuttle vectors by which is meant a DNA vehicle capable, naturally or by design, of replication in two different host organisms, which may be selected from bacteria and eukaryotic cells (e.g. mammalian, yeast or fungal).

25 The vector may also be a cloning vector which typically contains one or a small number of restriction endonuclease recognition sites at which nucleic acid segments can be inserted in a determinable fashion. Such insertion can occur without loss of essential biological function of the cloning vector. A cloning vector may also contain a marker gene that is suitable for use in the identification and
30 selection of cells transformed with the cloning vector. Examples of marker genes are tetracycline resistance, hygromycin resistance or ampicillin resistance. Many

cloning vectors are commercially available (Stratagene, New England Biolabs, Clonetech).

The nucleic acid segments of the invention may also be inserted into an expression vector. Typically an expression vector contains (1) prokaryotic DNA elements coding for a bacterial replication origin and an antibiotic resistance gene to provide for the amplification and selection of the expression vector in a bacterial host; (2) regulatory elements that control initiation of transcription such as a promoter; and (3) DNA elements that control the processing of transcripts such as introns, transcription termination/polyadenylation sequence.

Methods to introduce a nucleic acid segment into a vector are well known in the art (Sambrook et al., 1989). Briefly, a vector into which the nucleic acid segment is to be inserted is treated with one or more restriction enzymes (restriction endonuclease) to produce a linearized vector having a blunt end, a "sticky" end with a 5' or a 3' overhang, or any combination of the above. The vector may also be treated with a restriction enzyme and subsequently treated with another modifying enzyme, such as a polymerase, an exonuclease, a phosphatase or a kinase, to create a linearized vector that has characteristics useful for ligation of a nucleic acid segment into the vector. The nucleic acid segment that is to be inserted into the vector is treated with one or more restriction enzymes to create a linearized segment having a blunt end, a "sticky" end with a 5' or a 3' overhang, or any combination of the above. The nucleic acid segment may also be treated with a restriction enzyme and subsequently treated with another DNA modifying enzyme. Such DNA modifying enzymes include, but are not limited to, polymerase, exonuclease, phosphatase or a kinase, to create a polynucleic acid segment that has characteristics useful for ligation of a nucleic acid segment into the vector.

The treated vector and nucleic acid segment are then ligated together to form a construct containing a nucleic acid segment according to methods known in the art (Sambrook, 2002). Briefly, the treated nucleic acid fragment and the treated vector are combined in the presence of a suitable buffer and ligase. The mixture is then incubated under appropriate conditions to allow the ligase to ligate the nucleic acid fragment into the vector. It is preferred that the nucleic acid fragment and the vector

each have complimentary "sticky" ends to increase ligation efficiency, as opposed to blunt-end ligation. It is more preferred that the vector and nucleic acid fragment are each treated with two different restriction enzymes to produce two different complimentary "sticky" ends. This allows for directional ligation of the nucleic acid

5 fragment into the vector, increases ligation efficiency and avoids ligation of the ends of the vector to reform the vector without the inserted nucleic acid fragment.

Suitable procaryotic vectors include but are not limited to pBR322, pMB9, pUC, lambda bacteriophage, m13 bacteriophage, and Bluescript®. Suitable eukaryotic vectors include but are not limited to PMSG, pAV009/A+, PMTO10/A+,
10 pMAM neo-5, baculovirus, pDSVE, YIP5, YRP17, YEP. It will be clear to one of ordinary skill in the art which vector or promoter system should be used depending on which cell type is used for a host cell.

The invention also provides expression cassettes which contain a control sequence capable of directing expression of a particular nucleic acid segment of the
15 invention either *in vitro* or in a host cell. The expression cassette is an isolatable unit such that the expression cassette may be in linear form and functional in *in vitro* transcription and translation assays. The materials and procedures to conduct these assays are commercially available from Promega Corp. (Madison, Wisconsin). For example, an *in vitro* transcript may be produced by placing a nucleic acid segment
20 under the control of a T7 promoter and then using T7 RNA polymerase to produce an *in vitro* transcript. This transcript may then be translated *in vitro* through use of a rabbit reticulocyte lysate. Alternatively, the expression cassette can be incorporated into a vector allowing for replication and amplification of the expression cassette
25 within a host cell or also *in vitro* transcription and translation of a nucleic acid segment.

Such an expression cassette may contain one or a plurality of restriction sites allowing for placement of the nucleic acid segment under the regulation of a regulatory sequence. The expression cassette can also contain a termination signal operably linked to the nucleic acid segment as well as regulatory sequences required
30 for proper translation of the nucleic acid segment. Expression of the nucleic acid segment in the expression cassette may be under the control of a constitutive

promoter or an inducible promoter which initiates transcription only when the host cell is exposed to some particular external stimulus.

The expression cassette may include in the 5'-3' direction of transcription, a transcriptional and translational initiation region, a nucleic acid segment and a transcriptional and translational termination region functional *in vivo* and /or *in vitro*. The termination region may be native with the transcriptional initiation region, may be native with the nucleic acid segment, or may be derived from another source. Numerous termination regions are known in the art. Guerineau et al., Mol. Gen. Genet., 262:141 (1991); Proudfoot, Cell, 64:671 (1991); Sanfacon et al., Genes Dev., 5:141 (1991); Munroe et al., Gene, 91:151 (1990); Ballas et al., Nucleic Acids Res., 17:7891 (1989); Joshi et al., Nucleic Acid Res., 15:9627 (1987).

The regulatory sequence can be a nucleic acid sequence located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influences the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences can include, but are not limited to, enhancers, promoters, repressor binding sites, translation leader sequences, introns, and polyadenylation signal sequences. They may include natural and synthetic sequences as well as sequences which may be a combination of synthetic and natural sequences. While regulatory sequences are not limited to promoters, some useful regulatory sequences include constitutive promoters, inducible promoters, regulated promoters, tissue-specific promoters, viral promoters and synthetic promoters.

A promoter is a nucleotide sequence that controls expression of the coding sequence by providing the recognition for RNA polymerase and other factors required for proper transcription. A promoter includes a minimal promoter, consisting only of all basal elements needed for transcription initiation, such as a TATA-box and/or initiator that is a short DNA sequence comprised of a TATA- box and other sequences that serve to specify the site of transcription initiation, to which regulatory elements are added for control of expression. A promoter may be inducible. Several inducible promoters have been reported (Current Opinion in

Biotechnology, 7:168 (1996)). Examples include the tetracycline repressor system, Lac repressor system, copper-inducible systems, salicylate-inducible systems (such as the PR1a system). Also included are the benzene sulphonamide- (U.S. 5364,780) and alcohol-(WO 97/06269 and WO 97/06268) inducible systems and glutathione S-transferase promoters. In the case of a multicellular organism, the promoter can also be specific to a particular tissue or organ or stage of development.

An enhancer is a DNA sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue specificity of a promoter. It is capable of operating in both orientations (normal or flipped), and is capable of functioning even when moved either upstream or downstream from the promoter. Both enhancers and other upstream promoter elements bind sequence-specific DNA-binding proteins that mediate their effects.

The expression cassette can contain a 5' non-coding sequence which is a nucleotide sequence located 5' (upstream) to the coding sequence. It is present in the fully processed mRNA upstream of the initiation codon and may affect processing of the primary transcript to mRNA, stability of the mRNA, or translation efficiency (Turner et al., Molecular Biotechnology, 3:225 (1995)).

The expression cassette may also contain a 3' non-coding sequence which is a nucleotide sequence located 3' (downstream) to a coding sequence and includes polyadenylation signal sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor.

The invention also provides a construct containing a vector and an expression cassette. The vector may be selected from, but not limited to, any vector previously described. Into this vector may be inserted an expression cassette through methods known in the art and previously described (Sambrook et al., 1989). In one embodiment, the regulatory sequences of the expression cassette may be derived from a source other than the vector into which the expression cassette is inserted. In another embodiment, a construct containing a vector and an expression cassette is

formed upon insertion of a nucleic acid segment of the invention into a vector that itself contains regulatory sequences. Thus, an expression cassette is formed upon insertion of the nucleic acid segment into the vector. Vectors containing regulatory sequences are available commercially and methods for their use are known in the art

5 (Clonetech, Promega, Stratagene).

The expression cassette, or a vector construct containing the expression cassette may be inserted into a cell. The expression cassette or vector construct may be carried episomally or integrated into the genome of the cell.

A variety of techniques are available and known to those skilled in the art for

10 introduction of constructs into a cellular host. Transformation of bacteria and many eukaryotic cells may be accomplished through use of polyethylene glycol, calcium chloride, viral infection, phage infection, electroporation and other methods known in the art. Other transformation methods are available to those skilled in the art, such as direct uptake of foreign DNA constructs (see EP 295959), techniques of

15 electroporation (Fromm et al. Nature (London), 319:791 (1986) or high velocity ballistic bombardment with metal particles coated with the nucleic acid constructs (Kline et al. Nature (London) 327:70 (1987), and U.S. Patent No. 4,945,050).

The selection of an appropriate expression vector will depend upon the method of introducing the expression vector into host cells. Typically an expression

20 vector contains (1) prokaryotic DNA elements coding for a bacterial origin of replication and an antibiotic resistance gene to provide for the amplification and selection of the expression vector in a bacterial host; (2) DNA elements that control initiation of transcription, such as a promoter; (3) DNA elements that control the processing of transcripts, such as introns, transcription termination/polyadenylation

25 sequence; and (4) a reporter gene that is operatively linked to the DNA elements to control transcription initiation. Useful reporter genes include β -galactosidase, chloramphenicol acetyl transferase, luciferase, green fluorescent protein (GFP) and the like.

30 V. Methods to synthesize galactose- β (1,4)-N-acetylglucosamine moieties; glucose- β (1,4)-N-acetylglucosamine moieties; N-acetylgalactosamine- β (1,4)-N-

acetylglucosamine moieties; N-acetylgalactosamine- β (1,4)-glucose moieties; N-acetylglucosamine- β (1,4)-N-acetylglucosamine moieties; mannose- β (1,4)-N-acetylglucosamine moieties; and galactose- β (1,4)-N-acetylglucosamine-6-SO₃ moieties.

5 Catalytic domains of the invention having altered metal ion specificity can be used to catalyze the linkage of galactose and N-acetylglucosamine in the presence of a broad range of metal ions. Catalytic domains of the invention having altered metal ion specificity that are coupled with altered donor and/or acceptor specificity can be used to catalyze the linkage of numerous sugars from a donor to
10 numerous acceptor sugars in the presence of a broad range of metal ions. Linkage of sugar derivatives can also be achieved in the presence of a broad range of metal ions through use of the altered catalytic domains of the invention due to their expanded metal ion, donor, and acceptor specificity.

For example, in the presence of a broad range of metal ions, the catalytic
15 domains of section IA can be used to catalyze the linkage of galactose and N-acetylglucosamine; the catalytic domains of section IB can be used to catalyze the linkage of glucose and N-acetylglucosamine; the catalytic domains of section IC can be used to catalyze the linkage of N-acetylgalactosamine and N-acetylglucosamine; many of the catalytic domains described herein can be used in association with α -
20 lactalbumin to catalyze linkage of a sugar to glucose, as described in section ID; the catalytic domains of section IE can be used to catalyze the linkage of N-acetylglucosamine and N-acetylglucosamine, N-acetylgalactosamine to N-acetylglucosamine, and mannose to N-acetylglucosamine; and the catalytic domains of section IF can be used to catalyze the linkage of a donor and an acceptor having a
25 bulky side-group, such as linking galactose to N-acetylglucosamine-6-SO₃.

Acceptors may be free in solution or linked to another molecule. For example, an acceptor may be linked to a protein, another sugar, a sugar derivative, and the like. An acceptor may also be linked to a solid support that provides a platform to which donors may be added sequentially to form oligosaccharides, and
30 derivatives thereof, having a specified sequence.

Generally, the linkage between a donor and an acceptor is accomplished by incubating a catalytic domain of the invention with a desired donor and a desired acceptor under conditions of appropriate temperature, pH, and divalent metal concentration to allow linkage of the donor to the acceptor.

5 For example, the galactose and N-acetylgalactosyltransferase activity of β (1,4)-galactosyltransferase I can be determined using the following assay conditions. A 100 μ l incubation mixture containing 50 mM β -benzyl-GlcNAc, 10 mM MnCl₂, 10 mM Tris-HCl (pH 8.0), 500 μ M UDP-Gal or UDP-GalNAc, and 20 ng of β (1,4)-galactosyltransferase I can be incubated at 37°C for 10 minutes to

10 promote coupling of a donor sugar to an acceptor sugar. While these conditions are provided as an example, it is understood that many other conditions may be used to chemically link a donor to an acceptor using the altered catalytic domains of the invention.

15 VI. Methods to prepare oligosaccharides.

The invention provides methods to synthesize oligosaccharides, especially oligosaccharides having preselected sequences though use of the altered catalytic domains of the invention. Generally, the methods involve the sequential addition of a sugar, or derivative thereof, to the end of a growing oligosaccharide chain. Such 20 methods have been described using enzymes other than those of the invention (U.S. Patent No: 6,284,493).

Briefly, a donor and an acceptor may be incubated with an altered catalytic domain of the invention under conditions that allow the donor to be linked to the acceptor. These conditions are described in the examples section herein.

25 In one example, the donor and the acceptor may be combined with a catalytic domain of the invention in solution. The solution is then incubated to allow the donor to be linked to the acceptor. The newly linked molecule may be isolated and then added to a second solution containing a second donor and a second transferase enzyme. This cycle may be repeated with a specific donor added at each 30 cycle such that an oligosaccharide having a specific sequence is produced.

In another example, an acceptor may be linked to a solid support. The solid support may then be immobilized in a structure such as a column or a tray. A donor and a catalytic domain of the invention can then be incubated with the immobilized acceptor under conditions that allow the donor to be linked to the acceptor. The 5 solid support is then washed to remove any unlinked donor and catalytic domain present. A second donor and a second transferase enzyme can then be added and incubated under conditions that allow the donor to be linked to the acceptor. This cycle can be repeated to allow for the rapid and large-scale production of oligosaccharides having defined sequences. In addition, this method may be readily 10 adapted for use in an automated system. This system may be used without the need for protecting groups on the acceptor or the donor due to the use of enzymes that catalyze the linkage of a given donor to a given acceptor. Accordingly, an advantage of this method is that mild reaction conditions may be used that do not damage the growing oligosaccharide chain. Another advantage of the method is the 15 short cycling time required to add monomers onto the growing oligosaccharide chain due to the lack of a need to protect and deprotect the growing oligosaccharide chain.

Other methods for using the catalytic domains of the invention to synthesize sequences of predetermined oligosaccharides and derivatives thereof may also be 20 used. However, these methods will utilize an galactosyltransferase having an altered acceptor site, an altered donor site, or altered donor and acceptor sites.

VII. Methods to increase the immunogenicity of an antigen.

The invention provides methods to increase the immunogenicity of an 25 antigen. Generally, the methods involve incubating an antigen with a catalytic domain of the invention such that a sugar is transferred from a donor to an acceptor through the action of a catalytic domain.

The methods of the invention may be used in association with nearly any acceptor containing material against which an immune response is desired. For 30 example, sugars may be transferred from a donor to an acceptor that is linked to a whole cell. The cell can then be killed through irradiation or chemical means and

administered to an animal to elicit an immune response. Cell membranes may be used in a similar manner. Methods to create an immune response against cells and cell membranes are described in U.S. Patent No. 6,361,775.

The immunogenicity of a virus or subunit thereof may be increased

5 according to the methods of the invention and used as an improved vaccine. For example, for a virus that contains a glycoprotein as a component of the virion, one or more sugars may be added to the glycoprotein by propagation of the virus in a cell that expresses a catalytic domain of the invention. Alternatively, one or more sugars may be directly added to the glycoprotein using a catalytic domain of the

10 invention. Furthermore, there exist viruses without envelopes that contain complex carbohydrates. Sugars may be added onto these carbohydrates through use of a catalytic domain of the invention.

Viral subunits may be obtained from virions using biochemical methods or they can be expressed by recombinant means in suitable eukaryotic cells. Methods 15 of expressing viral subunits are common in the art. These methods may vary according to the type of virus used. For example, methods of expressing viral subunits are described in the following articles and in the references cited therein: Possee, Virus Research, 5:43 (1986); Kuroda et al., EMBO J., 5: 1359 (1986); Doerfler, Curr. Topics Microbiol. Immunol., 131:51 (1986); Rigby, J. Gen. Virol., 20 64:255 (1983); Mackett et al., In: DNA Cloning, A Practical Approach, Vol II, Ed. D. M. Glover, IRL Press, Washington, D.C. (1985); Rothestein, In: DNA Cloning, A Practical Approach, Supra (1985); Kinney et al., J. Gen. Virol., 69:3005 (1988); Panical et al., Proc. Natl. Acad. Sci., 80:5364 (1983); Small et al., In: Vaccinia Viruses as Vectors for Vaccine Antigens, pp. 175-178, Ed. J. Quinnan, Elsevier, 25 N.Y (1985).

Viruses for which vaccines are currently available and whose immunogenicity can be improved according to the methods of the invention include influenza virus (Orthomyxovirus); rabies virus (Rhabdovirus); hepatitis B virus (Hepadnavirus); eastern, western and Venezuelan equine encephalitis virus 30 (Togavirus/Alphavirus genus); and, Japanese encephalitis virus, tick-borne encephalitis virus and Russian spring-summer encephalitis virus (Flavivirus); Rift

Valley fever virus (Bunyavirus)(reviewed: Melnick, In: High Technology Route to Virus Vaccines Ed. Dreesman, Bronson and Kennedy, American Society for Microbiology, Washington, D.C. (1985); Ogra et al., Prog. Med. Virol., 37:156 (1990)). Viruses for which vaccines are not yet commercially available but which 5 may also be useful when treated according to the methods of the invention include, but are not limited to human immunodeficiency and human T-cell leukemia viruses (Retrovirus); respiratory syncytial virus and other paramyxoviruses (Paramyxovirus); herpes simplex viruses types 1 and 2, varicella zoster virus, cytomegalovirus and other herpes viruses (Herpesviruses); dengue virus and Saint 10 Louis encephalitis virus (Flavivirus); hantaan virus (Bunyavirus); Lassa virus (Arenavirus); and, rotavirus (Reovirus). In addition, there exist viral vaccines comprising live attenuated viruses the administration of which to humans is associated with some measure of risk of mild to severe side effects. It is now 15 possible according to the methods of the invention to enhance the immunogenicity of killed virus vaccines which may serve to reduce the use of their live, more risk-associated counterparts. Thus, vaccines which currently comprise live virus, such as measles virus, mumps virus, rubellavirus etc. are all encompassed by the invention.

Vaccines are prepared by suspension of a suitable concentration of an antigen that has been linked to a sugar, through the action of a catalytic domain of 20 the invention, in a pharmaceutically acceptable carrier. The composition of the carrier will depend upon the type of vaccine and the route of administration and will be readily apparent to one skilled in the art. The vaccine may be administered in a dose of 10^2 to 10^9 cells per dose (in the case of whole cells) or a similar equivalent of cell membranes. In the case of viral vaccines, virus may be administered in dose 25 ranging from 1 μ g to 50 mg of virus per dose, or a similar equivalent of subunit. Determination of the appropriate dosage of vaccine will be apparent to one of skill in the art and will depend upon the antigens comprising the vaccine, the age of the patient and their general and immunological health.

In order to improve the efficacy of vaccines prepared according to the 30 methods of the invention, patients may be pretreated with adjuvant at the site of vaccination several days prior to administration of vaccine. Pretreatment with

adjuvant serves to induce migration of macrophages to the site of inoculation, thereby enhancing the rate of phagocytosis of treated antigens. In the case of viral vaccines, patients may be treated with adjuvant and vaccine simultaneously. Adjuvants suitable for this purpose include aluminum hydroxide and like adjuvants.

5 Vaccines are administered to a mammal, particularly a human, either subcutaneously, intramuscularly, orally, intravenously, intradermally, intranasally or intravaginally. Prior to oral administration, the vaccine can be mixed with a solution containing a sufficient amount of sodium bicarbonate or other suitable compound capable of neutralizing stomach acid (approximately 2 grams).

10 Alternatively, the vaccine usually in lyophilized form, can be formulated as tablets which are treated with a coating capable of resisting stomach acid.

VIII. Method to stabilize platelets

The invention provides a method to stabilize blood platelets. Use of the
15 method allows blood platelets to be stored in the cold, which increases the shelf life of the platelets and reduces bacterial contamination. It is thought that cooling of platelets irreversibly reorganizes the von Willebrand factor receptor [the (GPIb α IX) $_2$ V complex] into clusters on the platelet surface. The integrin receptor $\alpha_M\beta_2$, (complement receptor type 3/Mac-1) of hepatic macrophages recognizes clustered
20 GPIb α , and the macrophages ingest the platelets. The interaction of GPIb α and macrophages can be blocked by galactosylation of exposed β -N-acetylglucosamine (Hoffmeister et al., Science, 301:1531 (2003)).

Accordingly, the method involves utilizing a catalytic domain or polypeptide of the invention to link a donor onto an acceptor that is attached to a platelet. The
25 method of the invention offers an advantage over previously methods in that the catalytic domains and polypeptides of the invention utilize magnesium instead of manganese during catalysis. Accordingly, the catalytic domains and polypeptides of the invention are active in blood, or in solutions of platelets obtained from blood.

It is thought that numerous donors may be used which will block interaction
30 between GPIb α and macrophages. These donors can be readily determined through use of methods known in the art and as described (Hoffmeister et al., Science,

301:1531 (2003)). In a particular embodiment, UDP-galactose is utilized as a donor.

Numerous acceptors are also thought capable of being used to block interaction of GPIb α and macrophages. These acceptors can be readily determined
5 through use of methods known in the art and as described (Hoffmeister et al.,
Science, 301:1531 (2003)). In a particular embodiment, β -N-acetylglucosamine is utilized as an acceptor.

In one example, the following method may be used to determine a donor that can be used to stabilize platelets. Platelets can be treated before or after being
10 chilled with a candidate donor and a catalytic domain or polypeptide of the invention. The treated platelets can be incubated with macrophages to determine if treatment with the donor causes the platelets to be resistant to ingestion by the macrophages. Acceptors can be identified by following the above described procedure and then identifying the acceptor onto which a donor was linked to defeat
15 interaction of the platelet with a macrophage.

Table I
Exemplary Amino Acid Sequences

SEQ ID NO	Accession Number	Description	Amino Acid Sequence
4	BAA06188	Human β (1,4)galactosyl-transferase (398 AA)	MRLREPLLSRSAAMPGASLQRACRLLVAVCA LHLGVTLVYYLAGRDLRLPQLVGVSTPLQG GSNSAAAIGQSSGDLRTGGARPPPGLASSQP RPGGDSSPVVDSDGPGPASNLTSPVPHTTALS LPACPEESPPLLGVGPMILIEFNMPVDLELVAKQN PNVKMGGRYAPRDCVSCHKVAIIPFRNRQE LKYWLYLHPVLQRQQLDYGIYVINQAGDTI FNRAKLLNVGFQEALKDYDYTECFVFSDVDLI PMNDHNAYRCFSQPRHISVAMDKGFLSPYV QYFGGVSVASSKQQFLTINGFPNNYWGWGGE DDDFNRLVFRGMSISRPNA VVGTCRMIRHSR DKKNEPNPQRFDRIAHTKETMLSDGLNSLY QVLDVQRYPLOYTQITVDIGTPS
5	A33396	Mouse β (1,4)galactosyl-transferase (399 AA)	MRFREQFLGGSAAMPGATLQRACRLLVAVC ALHLGVTLVYYLSGRDLSRLPQLVGVSSTLQ GGTNNGAAASKQPPGEQRPRGARPPPGLVSP KPRPGLDSSPGAASCPGLKSNLSSLPVPTTTG LLSLPACPEESPPLLGVGPMILDFNIAVDLELLAK KNPEIKTGGRYSPKDCVSCHKVAIIPFRNRQE HLKYWLYLHPILQRQQLDYGIYVINQAGDT MFNRAKLLNIGFQEALKDYDYNCFVFSDVDL IPMDDRNAYRCFSQPRHISVAMDKGFLSPY VQYFGGVSVASSKQQFLAINGFPNNYWGWG EDDDIFNRLVHKGMSISRPNAVGRCRMIRH SRDKKNEPNPQRFDRIAHTKETMRFDGLNSL TYKVLDVQRYPLOYTQITVDIGTPR
6	S05018	Bovine β (1,4)galactosyl-transferase (402 AA)	MKFREPLLGGSAAMPGASLQRACRLLVAVC ALHLGVTLVYYLAGRDLRLPQLVGVHPPLQ GSSHGAAIGQPSGEELRLRGVAPPPLQNSSK PRSRAPSNLDAYSHPGPGPGPSNLTSAPVPS TTTRSLTACPEESPPLLGVGPMILIEFNIPVDLKLIE QQNPKVKLGGRYTPMDCISPHKVAIILFRNR QEHLKYWLYLHPMVQRQQLDYGIYVINQA GESMFNRAKLLNVGFKEALKDYDYNCFVFS DVDLIPMDHNTYRCFSQPRHISVAMDKGFL SPYVQYFGGVSVASSKQQFLSINGFPNNYW WGGEDEDDIYNRLA FRGMSVSRPNAVIGKCR MIRHSRDKKNEPNPQRFDRIAHTKETMLSDG LNSLTVMLEVQRYPLOYTKITVDIGTPS

7		Human Stem Region of β (1,4)galactosyl- transferase	RDLRLPQLGVSTPLQGGNSAAIGQSSGD LRTGGARPPPLGASSQPRPGDSSPVVDSGP GPASNLTSPVPHTTALSACPEESPLLVGP MLIEFNMPVDLELVAKQ
8		Bovine Stem Region of β (1,4)galactosyl- transferase	RDLRLPQLGVHPPPLQGSSHGAAIGQPSG ELRLRGVAPPPLQNSSKPRSRAVSNLDAYSH PGPGPGCNSNLTSAPVPSTTR
9		Human Catalytic Domain of β (1,4)galactosyl- transferase	SLPACPEESPLLVGPMILIEFNMPVDLELVAKQ NPNVKMGGRYAPRDCVSPHKVAIIPFRNRQE HLKYWLYLHPVLQRQQLDYGIYVINQAGD TIFNRAKLLNVGFQEALKDYDTCFVFSVD LIPMNDHNAYRCFSQPRHISVAMDKGFSLP YVQYFGGVASSKQQFLTINGFPNNYWGWG GEDDDIFNRLVFRGMSISRPNAAVGTCRMIR HSRDKKNEPNPQRFDRIAHTKETMLSDGLNS LTYQVLDVQRYPLOYTQITVDIGTPS
10		Bovine Catalytic Domain of β (1,4)galactosyl- transferase	SLTACPEESPLLVGPMILEFNIPVDLKLIEQQN PKVKLGGRYTPMDCISPHKVAIILFRNRQE LKYWLYLHPMVQRQQLDYGIYVINQAGES MFNRAKLLNVGFKEALKDYDYNCFVFSVD LIPMNDHNTYRCFSQPRHISVAMDKGFSLPY VQYFGGVASLSKQQFLSINGFPNNYWGWG EDDDIYNRLAFRGMSVSRPNAVIGKCRMIRH SRDKKNEPNPQRFDRIAHTKETMLSDGLNSL TYMVLEVQRYPLOYTKitVDIGTPS

Table II
Exemplary Nucleic Acid Sequence

SEQ ID NO	Accession Number	Description	Nucleic Acid Sequence
11	D29805	Human β (1,4)galactosyl-transferase	ATGAGGCTTCGGAGCCGCTCCTGAGCCGGA GCCCGCGATGCCAGGCCTCGTACAGCG GGCCTGCCCTGCTCGTGGCCGTCTGCCGCTC TGCACCTTGGCGTCACCCTCGTTACTACCTG GCTGGCCGCGACCTGAGCCGCTGCCAAC TGGTCGGAGTCTCCACACCGCTGCAGGGCG GTCGAACAGTGCCGCCATCGGGCAGTCC TCCGGGGACCTCCGGACCGGAGGGGCCGGC CGCCGCCCTCTAGGCGCCTCTCCCAGCCG CGCCCCGGTGGCGACTCCAGCCCAGTCGTGG ATTCTGGCCCTGGCCCCGCTAGCAACTTGACC TCGGTCCCAGTGCCCCACACCACCGCACTGTC GCTGCCGCCCTGCCCTGAGGAGTCCCCGCTG CTTGTGGCCCCCATGCTGATTGAGTTAACAT GCTGTGGACCTGGAGCTGTGGCAAAGCAG AACCCAAATGTGAAGATGGCCGCCGCTATG CCCCCAGGGACTGCGCTCTCCTCACAAAGGT GGCCATCATCATTCAATCCGCAACCGGAG GAGCACCTCAAGTAAGCTGGCTATATTATTGCA CCCACTCCTGCAGGCCAGCAGCTGGACTAT GGCATCTATGTTATCAACCAGGCGGGAGACA CTATATTCAATCGTCTAAGCTCTCAATGTT GGCTTCAAGAAGCCTTGAAGGACTATGACT ACACCTGCTTGTGTTAGTGACGTGGACCTC ATTCCAATGAATGATCATAATGCGTACAGGT GTTTTCACAGCCACGGCACATTCCGTTGCA ATGGATAAGTTGGATTCAAGCTACCTTATGT TCAGTATTTGGAGGTGTCTCTGCTTCAAGTA AACAAACAGTTCTAACCATCAATGGATTCCCT AATAATTATTGGGCTGGGAGGAGAAGATG ATGACATTTTAACAGATTAGTTTAGAGGC ATGTCTATATCTCGCCCAAATGCTGTGGCG GACGTGTCGCACTGATCCGCCACTCAAGAGAC AAGAAAAATGAACCCAATCCTCAGAGGTTG ACCGAATTGCACACACAAAGGAGACAATGCT CTCTGATGGTTGAACTCACTCACCTACCAAGG TGCTGGATGTACAGAGATAACCCATTGTATAC CCAAATCACAGTGGACATCGGGACACCGAGC TAG

Example 1

Site-directed mutagenesis

Site-directed mutagenesis was performed using the polymerase chain reaction (PCR) method. Construction of the mutants was done using plasmid pEGT-d129 as the template. The pEGT-d129 plasmid contains a BamH I/EcoR I fragment inserted into a pET23a (Novagen, Madison, WI) vector that codes for residues 130 to 402 of bovine Gal-T1 (Boeggeman et al., *Protein Eng.*, **6**:779 (1993)), and has a Cysteine to Threonine exchange at the 342 amino acid residue position (C342T).

The nucleic acid sequences of the primers corresponding to the upper DNA strand that were used to create the M344H and M344E mutations are:

M344H: 5'ATCGGGAAAGACGCGT**CAC**ATCCGCCACTCGAGAGAC-3' (SEQ ID NO: 12), and

M344E: 5'ATCGGGAAAGACGCGT**GAG**ATCCGCCACTCGAGAGAC-3' (SEQ ID NO: 13). The restriction site Mlu I is underlined and the mutation codon in bold italics. Typically, the Gal-T1 DNA fragment between Mlu I to EcoR I was PCR-amplified using the terminal cloning primer and the mutagenesis primer. The fragment was cut with the restriction enzymes Mlu I and EcoR I and ligated with the pre-cut plasmid pEGT-129 DNA with the same enzymes. Mutants were screened for the presence of full Gal-T1 DNA, and then sequenced. The positive clones were transformed into BL21(DE3) pLysS cells as described previously (Ramakrishnan et al., *J. Mol. Biol.*, **310**:205 (2001)). The mutant proteins were expressed and purified according to the published method (Ramakrishnan et al., *J. Mol. Biol.*, **310**:205 (2001)).

The role of the Met344 residue in the structure and function of β4Gal-T1 was investigated by mutating it to a histidine or glutamic acid residue. These amino acids were chosen to retain the coordination bond with the primary metal ion. Substitution of Met344 with Ala or Gln would have eliminated the coordination bond (Boeggeman and Qasba, *Glycobiology*, **12**:395 (2002)).

30

Example 2

Protein expression and purification

For protein expression BL21 (λ DE3)/pLysS-competent cells were transformed with the pET vector derivatives according to the manufacturer's protocols. The transformed cells were grown in LB broth containing 50 μ g/ml¹ ampicillin to an OD600 nm of about 0.7, followed by induction with 0.4 mM IPTG. Cultures were harvested after 3-4 hours by centrifugation at 2000 x g for 20 minutes. The inclusion bodies were isolated and solubilized as described (Boeggeman et al., *Protein Eng.*, 6:779-785 (1993)). From a liter of induced bacterial culture, the yield is generally 80 to 100 mg of purified inclusion bodies. Novex gels were used for SDS-PAGE analysis and the protein bands were visualized with Coomassie blue. Protein concentrations were measured with the Bio-Rad protein dye reagent with bovine serum albumin as the standard.

An S-sulfanation protocol was used for folding the protein obtained from the inclusion bodies (Boeggeman et al., *Protein Eng.*, 6:779-785 (1993)). Inclusion bodies (100 mg) were dissolved in 10 ml of 5 M guanidine hydrochloride (Gu-HCl) with 0.3 M sodium sulfite at room temperature. To sulfonate all of the free thiol groups in the protein molecule, 1 ml of 50 mM S-sulfonating agent, 2-nitro-5-(sulfothio)-benzoate (NTSB) was added to the solution and stirred vigorously. Completion of sulfonation was judged by the color change of the solution from red to pale yellow. The protein solution was then diluted tenfold with water to precipitate the sulfonated protein. The sulfonated protein was re-dissolved in 5 M Gu-HCl to a protein concentration of 1 mg/ml, which has an absorption of 1.9 to 2.0 at 275 nm. The protein solution was diluted tenfold in 10 ml portions in a folding solution to give a final concentration of 100 μ g/ml, 0.5 M Gu-HCl, 50 mM Tris-HCl (pH 8.0 at 4°C), 5 mM EDTA, 4 mM cysteamine, and 2 mM cystamine. The protein was allowed to fold for 48 hours at 4°C and was then dialyzed against three 4 liter changes of 50 mM Tris-HCl (pH 8.0), 5 mM EDTA, 4 mM cysteamine, 2 mM cystamine at 4°C to remove Gu-HCl. The protein that precipitated during dialysis was removed by centrifugation and the supernatant was concentrated. Typically when 100 mg of sulfonated wild-type d129-B4GalT1 is folding in a 1 liter

folding solution, it yields 3 to 5 mg of active, soluble, and pure protein. The folded active B4GalT-1 was further purified by affinity chromatography using an LA-agarose column.

5

Example 3

β 4Gal-T Enzyme Assays

Protein concentrations were measured using the Bio-Rad Protein Assay kit, based on the method of Bradford and further verified on PAGE-SDS gels using standard protein concentration markers. An *in vitro* assay procedure for Gal-T1 has 10 been reported previously (Ramakrishnan et al., *J. Mol. Biol.*, 310:205 (2001)). The activities were measured using UDP-Gal as sugar nucleotide donor, and GlcNAc as the acceptor sugar. For the specific activity measurements, a 100- μ l incubation mixture containing 25 mM GlcNAc, 5 mM MnCl₂ or MgCl₂, 20 mM Tris-HCl, pH 8.0, 500 μ M UDP-Gal 500 ng M344H-Gal-T1 or 30 ng of C342T-Gal-T1 and 0.5 15 μ Ci ³H-UDP-Gal was used for each Gal-T reaction. The incubation was carried out at 30 °C for 15 minutes. The reaction was terminated by adding of 200 μ l cold water, and the mixture was passed through a 0.5 ml bed volume column of AG 1-X8 cat ion resin (Bio-Rad) to remove any un-reacted ³H-UDP-Gal. The column was washed successively with 300, 400 and 500 μ l of cold water, and the column flow- 20 through was diluted with Biosafe scintillation fluid; radioactivity was measured with a Beckman counter. A reaction without the acceptor sugar was used as a control. Only 0.1 mM concentration of ZnCl₂ or CoCl₂ was used whenever Zn²⁺ or Co²⁺ was used during the enzyme assay.

Previous studies have shown that ions of alkaline earth metals, such as Mg²⁺, 25 Ca²⁺ or Sr²⁺, do not activate the wild-type β 4Gal-T1 as they do not bind to the primary metal binding site of the enzyme (Powell and Brew, *J. Biol. Chem.*, 251:3645 (1976); Boeggeman and Qasba, *Glycobiology*, 12:395 (2002)) (Table II). When the mutants, M344H-Gal-T1 and M344E-Gal-T1, were tested for their catalytic activity in the presence of several metal ions, including alkaline earth 30 metals, they showed metal ion activation specificities different from the wild-type β 4Gal-T1 (Table II). Surprisingly, the catalytic activity for the M344H-Gal-T1

mutant is better with the Mg^{2+} than with the Mn^{2+} preferred by the native enzyme. Although its specific activity using manganese ion is low compared to the wild type, its activity in the presence of the Mg^{2+} is nearly one-fourth of the wild type with the Mn^{2+} . This value is similar to that of the wild-type enzyme in the presence of Zn^{2+} .

5 Although the mutant M344E-Gal-T1 exhibits low levels of enzyme activity in the presence of Mn^{2+} , Co^{2+} or Zn^{2+} , the activity with each was similar to the maximum activity observed at 100 μM concentrations of the metal ions (Table II). Similar to the behavior of the wild-type enzyme, higher concentrations of Co^{2+} and Zn^{2+} inhibit the activity of M344E-Gal-T1, whereas manganese does not exhibit this

10 effect.

The activation curve of M344E-Gal-T1, using Mn^{2+} , is strikingly different from that of the wild-type enzyme (Figure 1A and 1B). In contrast to the wild type enzyme, the velocity curve obtained with the Mn^{2+} concentration for the M344E-Gal-T1 mutant is not sigmoidal. On the other hand, the same curve for the M344H-Gal-T1 mutant in the presence of the Mg^{2+} is sigmoidal (Figure 1C). The observation that activation of the wild type enzyme by metal ions is sigmoidal has been interpreted as involving two metal binding sites in the enzyme: one with high affinity which is associated with low velocity, and a second site with low affinity which is associated with high velocity (Powell and Brew, *J. Biol. Chem.*, **251**:3645 (1976); Boeggeman and Qasba, *Glycobiology*, **12**:395 (2002)). A similar sigmoidal velocity curve for the M344H-Gal-T1 mutant with Mg^{2+} is also suggestive of two metal binding sites, with Mg^{2+} binding not only to the first site but also to the second metal binding site. The K_d values for Mg^{2+} binding by sites I and II are comparable to those for Mn^{2+} binding by wild-type enzyme (Table III). The K_{d1} value for Mg^{2+} by the mutant, the binding to the primary metal binding site, is only fivefold higher than for Mn^{2+} with the wild type, whereas the K_{d2} value, the binding to the second metal binding site, is 15 times higher. However, the K_{d2} value is only fivefold higher than the value reported for the Ca^{2+} binding to the second site in the wild-type enzyme (Powell and Brew, *J. Biol. Chem.*, **251**:3645 (1976)). The binding constants for Mg^{2+} binding by the mutant are only moderately high. Due to strong inhibition of the catalytic activity by the acceptor (Table II), Mn^{2+} dependent

activity of M344H-Gal-T1 could not be measured. Since the M344E-Gal-T1 mutant exhibits a non-sigmoidal activation curve (Figure 1B), a single metal binding site model was used for calculating the kinetic constants. The binding constant K_1 for this site is 0.5 μM , fifty-fold lower than the binding to the primary site of the wild type, indicating that the Mn^{2+} binds very tightly to the primary binding site of M344E-Gal-T1.

The metal ion activation curves indicate that mutation of Met344, the residue in the primary metal binding site of the wild type enzyme, affects the secondary metal binding site strongly. To understand effect, the crystal structure analysis of the M344H-Gal-T1 mutant together with enzyme kinetics, in the presence of Mg^{2+} , was analyzed.

Mn^{2+} at higher GlcNAc concentrations inhibits the catalytic activity of the mutant. This effect was not observed with Mg^{2+} . In comparison, non-competitive inhibition was observed at high GlcNAc concentrations with the wild-type enzyme (Morrison and Ebner, *J. Biol. Chem.*, 246:3977 (1971)).

In the presence of Mn^{2+} , inhibition of the catalytic activity of the M344H-Gal-T1 mutant was observed at GlcNAc concentrations of 3 to 7 mM (Figure 5), whereas only much higher GlcNAc concentrations are known to inhibit the catalytic activity of the wild-type enzyme (Morrison and Ebner, *J. Biol. Chem.*, 246:3977 (1971)). Under the same measurement conditions, the catalytic activity of the mutant M344H-Gal-T1 was not inhibited due to the increased GlcNAc concentration in the presence of Mg^{2+} (Figure 5). Inhibition at excess acceptor concentrations has been shown to result from formation of a dead-end enzyme• Mn^{2+} •UDP•acceptor complex (Bell et al., *J. Biol. Chem.*, 251:3003 (1976)). In this step the metal ion plays an important role which can be described on the basis of the conformational flexibility of the mutant in the presence of different metal ions.

During the catalytic cycle, upon binding of the metal ion and UDP-Gal, β 4Gal-T1 undergoes a conformational change from an open to a closed structure. In the open confirmation the long loop is placed in such a way that its His347 residue is away from the metal binding site. In the closed conformation, the His residue

forms a strong coordination bond with the metal ion. This creates the acceptor-binding site of the enzyme. After catalysis and product release, the closed conformation reverts to the open conformation which exposes the UDP and metal ion to the solvent environment and starts a new cycle.

5 The primary metal binding site is situated at the N-terminal hinge region of the long loop, whereas the metal binding residues, Met344 and His347, flank the hinge residue Ile345 (Figure 6). Since His347 can coordinate with the metal ion only when β 4Gal-T1 is in the closed conformation (Ramakrishnan and Qasba, *J. Mol. Biol.*, 310:205 (2001)), the metal ion coordination with β 4Gal-T1 changes
10 during the catalytic cycle. In the open conformation, the metal ion has only two coordination bonds with the residues of β 4Gal-T1, one with Asp254 and the other with Met344. Of these, the coordination with Met344 being weak, the product UDP and Mn^{2+} are easily released.

In contrast, in the M344H-Gal-T1 mutant, the metal ion may not be released
15 as easily as in the wild-type enzyme due to stronger coordination of Mn^{2+} with the His residue. This “sticky” Mn^{2+} may not only hinder the release of UDP, but may also facilitate binding of GlcNAc in the absence of UDP-Gal. Inhibition by the acceptor, even at low concentrations, may have been due to this effect. Since Mg^{2+} is a less preferred metal ion than Mn^{2+} for coordination with the His residue, this
20 “sticky” effect may be absent. These results show that the metal ion plays a role in determining the k_{cat} of the enzyme reaction by participating in the conformational cycling of the enzyme, as well as in the formation and stabilization of the transition state complex during catalysis.

The observation of a sigmoidal curve (Figure 1C) for the activation of the
25 M344H-Gal-T1 mutant by Mg^{2+} can be explained by the presence of two metal binding sites. However, other factors that may also contribute to the enhanced activity at high metal concentrations. At the end of the catalytic cycle, in order to release the bound UDP and Mg^{2+} , the enzyme has to change to an open conformation. At this stage, the faster it releases UDP, the sooner it attains the open
30 conformation to start a new catalytic cycle. Since UDP has a strong affinity for a

metal ion, the free metal ion concentration has to be sufficiently high enough to efficiently release the bound UDP from the enzyme•Mg²⁺•UDP complex. In the enzyme•Mg²⁺•UDP complex of the mutant, Mg²⁺ is most suitable metal ion to dislodge the bound UDP molecule. In the wild-type enzyme, a relatively high 5 concentration of Mn²⁺ enables the faster release of UDP from the enzyme. A similar mechanism may be responsible for the enhanced catalytic activity in the presence of various cations such as spermine and spermidine at low concentrations of Mn²⁺ (Baker and Hillegass, Arch. Biochem. Biophys., 165:597 (1974); Navaratnam et al., Biochem. Jour., 239:423 (1986)).

10

Example 4

Determination of Kinetic Constants

The enzyme activation data at various concentrations of Mg²⁺ were fitted to an equation describing metal binding to a high affinity site (K_1) to generate an 15 enzyme form with a low k_{cat} (V_1) and to a second, lower affinity site (K_2) to generate a form with a higher k_{cat} (V_2) (Boeggeman and Qasba, Glycobiology, 12:395 (2002)):

$$v = \frac{[Mg] (V_1 * K_2 + V_2 * [Mg])}{(K_1 * K_2 + K_2 * [Mg] + [Mg] * [Mg])} \quad 20$$

The true K_m of the donor (K_A) and of the acceptor (K_B), the dissociation

$$v = \frac{[Mg](V_1 * K_2 + V_2 * [Mg])}{(K_1 * K_2 + K_2 * [Mg] + [Mg] * [Mg])}$$

constant of the donor, K_{ia} , and k_{cat} , were obtained using two-substrate analyses and

25 the primary plots of at least five concentrations of donor (UDP-Gal) and five concentrations of acceptor, and the corresponding secondary plots of the intercepts and slopes. Initial rate conditions were linear with respect to time. A suitable range of donor and acceptor concentrations was chosen, which allowed accurate Michaelis-Menten constants to be derived. The data were also analyzed for a

general two-substrate system using the following equations (Herbert, Initial Rate Enzymatic Kinetics, Springer-Verlag, New York (1975)) with the software EnzFitter, a Biosoft non-linear curve fitting program for Windows:

5 Equation 1: $v = \frac{V_{max} [A] [B]}{K_{ia} K_B + K_B[A] + K_A[B] + [A][B]}$

10 Equation 2: $v = \frac{V_{max} [A] [B]}{K_B[A] + K_A[B] + [A][B]}$

Here v is the initial velocity and the rate equation for a sequential symmetrical initial velocity pattern associated with equation 1, an ordered or random equilibrium mechanism in which substrate A dissociates well from the E•S complex with a dissociation constant of K_{ia} . Equation 2 is for an asymmetric initial velocity pattern for a double-displacement or “ping-pong” mechanism. The kinetic parameters K_A , K_B , K_{ia} , and V_{max} were obtained from the fitted curves, using the above rate equations. The graphical method and EnzFitter program gave very similar kinetic parameters. In the β4Gal-T assay, the maximum substrate concentrations used for UDP-Gal and GlcNAc were 2 mM and 80 mM, respectively (which are threefold higher than their K_m values).

Since M344H-Gal-T1 exhibits high catalytic activity in the presence of Mg²⁺, a double substrate kinetic study was carried out in order to determine the kinetic constants for both the donor (UDP-Gal) and acceptor (GlcNAc) molecules in the presence of the Mg²⁺ and compared with those of the wild-type enzyme in the presence of the Mn²⁺ (Figure 2A and 2B). The kinetic data fits best to a rate equation that lacks a K_{ia} term (Equation 2), describing an asymmetric initial velocity pattern associated with a sequential or “ping-pong” mechanism in which donor substrate does not dissociate from the enzyme-substrate complex. This is quite similar to that of the wild-type enzyme (Figure 2B) (Takase and Ebner, Curr. Top. Cell Regul., 24:51 (1984); Boeggeman and Qasba, Glycobiology, 12:395 (2002)).

In the β 4Gal-T reaction the true K_m value for the acceptor and donor for the mutant are nearly two- and fivefold higher, respectively, than the wild-type β 4Gal-T1 (Table III). Although the catalytic efficiency with respect to donor and acceptor, compared to the wild-type enzyme with Mn^{2+} , has decreased by an order of about 13 and 6, respectively, the turnover number of the mutant, k_{cat} , is reduced by only 60%. The lesser effect on k_{cat} could be the result of Mg^{2+} participating more efficiently in the formation of the transition state complex during the transfer reaction by the mutant or minor differences in the coordination geometry of the Mg^{2+} in the mutant compared to that of Mn^{2+} ion in the wild-type enzyme. The crystal structure of the M344H-Gal-T1 in complex with UDP-Gal in the presence of either Mn^{2+} or Mg^{2+} was then determined and compared to the structure with the wild-type UDP-Gal•metal complex. Crystal structure analysis of the M344E-Gal-T1 mutant in the presence of UDP-Gal and Mn^{2+} was conducted to further understand the effect of the M344E mutation on the metal-ion binding site.

15

Example 5

Crystal Structure Determination

The mutant M344H-Gal-T1 was co-crystallized in the presence of UDP-Gal and $MnCl_2$ or $MgCl_2$ while the M344E-Gal-T1 mutant was crystallized in the presence of UDP-Gal and $MnCl_2$. The crystals were grown at room temperature by the hanging drop method, using 30 mg/ml of the mutant protein, 17 mM of UDP-Gal, and 17 mM $MgCl_2$ or $MnCl_2$, with the precipitant containing 10% (v/v) dioxane, 100 mM mes-NaOH buffer (pH 6.5) and 2.0 M ammonium sulfate. Complete three-dimensional x-ray diffraction data were collected at beam line X9B, NSLS, Brookhaven National Laboratory (Upton, New York), using a Quantum-4 ccd detector. The frames were processed using HKL2000 (Otwinowski and Minor, Methods Enzymol., 276:307 (1997)). The crystal and data collection parameters are listed in Table 1.

Since the crystals were isomorphous with the C342T-Gal-T1•UDP-Gal• Mn^{2+} complex crystals, that structure was used as a starting model without any substrate. An initial model containing Ala at residue 344 was used. After initial

refinement, the difference Fourier electron density maps not only confirmed the mutation, but also revealed the UDP-Gal and Mn²⁺ or Mg²⁺ bound to the enzyme. These features were included in the further refinement. All the refinements were carried out by CNS1.0 (Brunger et al., *Acta Crystallogr.*, **D54**:905 (1998)). The 5 final refinement statistics are given in Table I. All figures were drawn using graphic programs MOLSCRIPT (Karulis, *J. Appl. Crystallogr.*, **24**:946 (1991)), BOBSCRIPT (Esnouf, *Acta Crystallogr.*, **D55**:938 (1999)), and Grasp (Nicholls et al., *Proteins*, **11**:281 (1991)). The coordinates have been deposited in the Protein Data Bank.

10 The wild-type β4Gal-T1 crystallized in the presence of UDP-Gal and MnCl₂, while the M344-Gal-T1 mutants crystallized in the presence of UDP-Gal with either MnCl₂ or MgCl₂. The crystal structure of both mutants was determined, M344E-Gal-T1 in the complex with UDP-Gal and Mn²⁺, and M344H-Gal-T1 in complex with UDP-Gal and Mn²⁺ or Mg²⁺ (Table I). The three-dimensional crystal 15 structures of these complexes are quite similar. The β4Gal-T1 mutant proteins were found in the closed conformation (Figure 3A), similar to the wild-type complex with UDP-Gal•Mn²⁺ (PDB: 1O0R) (Ramakrishnan et al., *J. Mol. Biol.*, **318**:491 (2002); Ramakrishnan and Qasba, *J. Biomol. Struct. Dyn.*, **21**:1 (2003)). The r.m.s. deviations between these structures and the closed structure of the wild-type β4Gal- 20 T1 varies between 0.4 and 0.6 Å on the Cα atoms, indicating that neither the mutation nor the binding of Mg²⁺ caused any significant change in the structure.

The metal nucleotide complex can be clearly located in the crystal structure of the M344H-Gal-T1•UDP-Gal•Mg²⁺ complex (Figure 3B). Furthermore, in the crystal structures of M344H-Gal-T1•UDP-Gal•metal complexes, the presence of 25 the different metal ions could easily be identified from the difference Fourier maps. When the difference Fourier electron density at the metal ion position was compared with the electron densities of the phosphate groups of UDP-Gal in M344H-Gal-T1•UDP-Gal•Mn²⁺, the electron density at the metal ion position was stronger than at the phosphate groups of UDP-Gal. In M344H-Gal-T1•UDP-Gal•Mg²⁺, the 30 electron density at the metal ion position was weaker than at the phosphate groups. In these structures the metal ions exhibit six similar coordination bonds with

comparable bond distances (Table IV). The stereochemistry of the Mg²⁺ coordination is quite similar to that of the Mn²⁺ (Table IV) (Ramakrishnan et al., *J. Mol. Biol.*, **318**:491 (2002); Ramakrishnan et al., *J. Biomol. Struct. Dyn.*, **21**:1 (2003)). As before, the second metal ion could not be located in the present studies.

5 Comparison of the crystal structures of M344H-Gal-T1•UDP-Gal•metal complexes (Figure 4B and 4C) show that the presence of the Mg²⁺ has not perturbed the interactions between the UDP-Gal and the protein molecule, the interactions being similar to those found in the crystal structure of the wild-type protein, β4Gal-T1, in complex with UDP-Gal•Mn²⁺ (PDB:1O0R) (Ramakrishnan et al., *J. Mol.*
10 *Biol.*, **318**:491 (2002); Ramakrishnan and Qasba, *J. Biomol. Struct. Dyn.*, **21**:1 (2003)). However, the coordination distance between the atom Ne2 of the His344 to the metal ion is shorter (2.2 – 2.5 Å) than the corresponding coordination distance found for the sulfur atom of Met344 in the wild type (2.7 Å). These results indicate that the presence of the His residue at 344 strengthens the metal ion binding to the
15 enzyme. Even though the coordination geometry of the Mn²⁺ and Mg²⁺ bound to the M344H-Gal-T1 mutant is very similar, the higher chelating effect by the His residue on the transition metal ion over an alkali earth metal ion could hinder formation of the enzyme transition state complex during catalysis. This is supported by the observed reduction in enzyme activity by the mutant in the presence of Mn²⁺.

20 In all these crystal structures, mutation of Met344 does not affect binding of UDP-Gal (Figure 4A, 4B, and 4C). Substitution of Met344 with Glu344 seems to have been very well accommodated in the crystal structure which enhances binding affinity, as reflected in the K_i value (0.5 μM). One of the carboxylate oxygen atoms of the Glu344 forms a strong coordination bond (2.1-2.2 Å) with the Mn²⁺, while the
25 other oxygen atom forms a hydrogen bond with the Lys279 (Figure 4A). In M344H-Gal-T1•UDP-Gal•metal complexes (Figure 4B and 4C) and the wild-type crystal structure with Mn²⁺, the same Lys279 was found to hydrogen-bond with the β-phosphate oxygen atom of the bound UDP-Gal molecule. This may produce the high affinity of the Mn²⁺ for the primary metal binding site of M344E mutant (0.5
30 μM, derived from Figure 1B using single binding-site model) compared to the wild-type enzyme. The presence of a strong coordination bond between the residue 344

and the metal ion may result in the hindrance for the formation of the transition state complex during catalysis, resulting in low k_{cat} values.

Example 6

5

Platelet Protocols

Platelets can be isolated from human volunteers using a metrizamide gradient or a Sepharose column (Falet et al., *Blood*, **96**:3786 (2000); Hoffmeister et al., *Cell*, **10**:87 (2003)). Human platelets for use in *in vitro* phagocytosis assays can be suspended at a concentration of 10^9 per milliliter in 140 mM NaCl, 3 mM KCl,
10 0.5 mM MgCl₂, 5 mM NaHCO₃, 10 mM glucose, and 10 mM Hepes (pH 7.4) (Buffer A). The platelets can be labeled with 1.8 μ M CM-Orange for 10 minutes at 37°C and diluted 10 X with Buffer A before enzymatic galactosylation.

Murine blood can be obtained from anesthetized mice using 3.75 mg/gram of Avertin (Fluka Chemie, Steinheim, Germany) by retro-orbital eye bleeding into
15 0.1 volume of Aster-Jandl anticoagulant and centrifuged at 300 x g for 8 minutes at room temperature to obtain platelet rich plasma (PRP). Platelets can be separated from plasma by centrifugation at 1200 x g for 5 minutes and washed twice in 140 mM NaCl, 5 mM KCl, 12 mM trisodium citrate, 10 mM glucose, and 12.5 mM sucrose, 1 μ g/ml PGE₁ (pH 6.0) (Buffer B) by centrifugation. Washed platelets can
20 be resuspended at a concentration of 1×10^9 / ml in Buffer A. The platelets can be labeled with 5 uM CMFDA for 15 minutes at 37°C, and diluted 10 X with Buffer A before enzymatic galactosylation (Hoffmeister et al., *Cell*, **10**:87 (2003)).

GPIb α can be enzymatically cleaved from the surface of chilled or room temperature maintained human platelets with 10 μ g/ml of snake venom
25 metalloprotease mocoahagin in Buffer A containing 1 mM Ca⁺² (Ward et al., *Biochemistry*, **28**:8326 (1996)). After enzymatic digestion, the platelets can be washed by centrifugation and the extent of GPIb α removal from the platelet surface can be monitored by flow cytometry (FACScalibur Flow Cytometer, Becton Dickinson Biosciences, San Jose, CA) using 5 μ g/ml of FITC-conjugated anti-
30 GPIb α SZ2 antibody (Immunotech, Marseille, France).

Terminal β -N-acetylglucosamine and β -N-acetylgalactosamine residues can be removed from the surface of platelets using 100 U/ml β -N-Acetyl-hexosaminidase (NEB, Beverly, MA) in 50 mM sodium citrate buffer (pH 6.0) for 30 minutes at 37°C. Enzymatically treated platelets can be washed by

5 centrifugation at 850 x g in a 5 X volume of Buffer B and resuspended at a concentration of 10^8 cells/ml in Buffer A.

The effects of chilling on platelet survival and function of mouse or human plates can be determined by incubating the cells at room temperature (about 25°C) or on ice for two hours and then rewarming the cells at 37°C before transfusion into

10 mice or *in vitro* analysis.

Platelets can be enzymatically galactosylated. Human or murine platelets that are labeled with CM-Orange (about 10^8 cells / ml) can be chilled for about 2 hours, rewarmed, and incubated with 200 μ M uridine 5'-diphosphogalactose (UDP-Gal), in the presence of absence of 20 mU of active, or as a control, heat inactivated

15 (10 minutes at 95°C) β 4-galactosyltransferase (β 4GalT1) for 30 minutes at 37°C. The platelets can be washed by centrifugation at 850 x g for 5 minutes with 5 volumes of Buffer B following galactosylation.

Murine platelets can be labeled with 5 μ M CMFDA for 30 minutes at 37°C can be chilled for 2 hours, rewarmed, and treated using the galactosylation protocol

20 as described for the human platelets above. The platelets can be suspended at 3 x 10^8 cells / ml in Buffer A before being injected into mice.

Platelet circulation can be assayed. CMFDA-labeled murine platelets at 1 x 10^8 cell / ml that are chilled or room temperature can be injected via the lateral tail vein into mice of the same strain and age. Blood samples can be collected

25 immediately (less than two minutes) and at 0.5, 2, 24, 48, and 72 hours after transfusion into 0.1 ml volume of Aster-Jandl anticoagulant. The percentage of CMFDA positive platelets, recoveries, and platelet counts can be determined through use of flow cytometry (Hoffmeister et al., *Cell*, 10:87 (2003); Baker et al., *Am. J. Hematol.*, 56:17 (1997)).

30 In vitro phagocytic assays are known in the art. Monocytic THP-1 cells (ATCC, Manassas, VA) can be cultured for 7 days in RPMI 1640 culture medium

supplemented with 10% fetal bovine serum, 25 mM Hepes, 2 mM glutamine, and differentiated using 1 ng/ml TGF β and 50 nM 1,25-(OH)₂ vitamine D3 (Calbiochem, San Diego, CA) for 24 hours. Differentiation is accompanied by increased expression of $\alpha_M\beta_2$ integrin (Simon et al., *J. Exp. Med.*, 192:193 (2000)).

5 Differentiated THP-1 cells at 2×10^6 cells / ml can be plated onto 24-well plates and allowed to adhere for 45 minutes at 37°C. The cells can be activated by addition of 15 ng/ml PMA for 15 minutes. CM-Orange-labeled, chilled or room temperature platelets at 10^7 cells / well that were previously subjected to different treatments can be added to the phagocytes in Ca⁺² and Mg⁺² containing HBSS (Gibco Invitrogen, Grand Island, NY) or monosaccharide solutions dissolved in Ca⁺² and Mg⁺² containing HBSS and incubated for 30 minutes at 37°C. The phagocyte monolayer can be washed 3 times with HBSS, and adherent platelets can be removed by treatment with 0.05% trypsin/0.53 mM EDTA in HBSS at 37°C for 5 minutes followed by 5 mM EDTA at 4°C to detach the macrophages for flow cytometry analysis. the macrophages can be gated and 10,000 events can be acquired for each sample.

Platelets can be labeled with lectins. Chilled or room temperature maintained platelets with or without treatments as described above, can be incubated with 2 μ g/ml FITC-conjugated succinylated tritium vulgaris-wheat germ agglutinin (S-WGA) or 2.5 μ g/ml FITC-conjugated ricinus communis I lectin (RCA I) for 30 minutes at room temperature. Platelet samples can be analyzed immediately by flow cytometry with 10,000 events being analyzed per sample.

Platelets can be immunolabeled and assessed with flow cytometry. Washed murine or human platelets that are chilled or maintained at room temperature can be exposed to 0.01, 0.1, and 6 U/ml thrombin. or 0.06, 0.6, and 6 μ g/ml CRP for 5 minutes at 37°C. Enzymatic galactosylation can be carried out as described herein. The samples can be diluted (1:100) in PBS (Gibco Invitrogen, Grand Island, NY) and resting or activated platelets can be analyzed by flow cytometry for surface expression of CD62P by staining with FITC-conjugated mAb (5 μ g/ml) for 20 minutes at room temperature with 10,000 events analyzed per sample.

Human blood can be obtained from volunteers and stored. PRP can be generated by centrifuging the blood at 250 x g for 20 minutes at room temperature and allowing the cells to rest for 30 minutes at 37°C. The PRP can be separated into three equal volumes with sample 1 being untreated, sample 2 being incubated with

5 200 µM UDP-GAL for 30 minutes at 37°C before being placed at 4°C, and sample 3 being placed at 4°C. Galactose transfer can be performed after chilling the PRP for 1, 2, and 12 days. Prior to galactosylation, sample 3 can be rewarmed to 37°C for 15 minutes and galactosylation can be achieved in PRP by adding 200 µM UDP-GAL and incubating the cells at 37°C for 30 minutes. To determine S-WGA and

10 RCA 1 binding at day 0, 1, 2, and 12, platelets from the 3 samples can be isolated by centrifugation and resuspended in Buffer A at a platelet concentration of 10⁸ cells / ml.

For immunoblot and immunoprecipitation analysis, isolated platelets can be treated with molarhagin as described above. Platelets can be lysed immediately

15 with 4X SDS-PAGE loading buffer containing 5% β-mercaptoethanol (Laemmli, *Nature*, 227:680 (1970)). Molarhagin-treated platelets can be centrifuged at 800 x g for 5 minutes and the resultant pellet and supernatant can be separated. The platelet pellet can be washed 3 times by centrifugation in Buffer B and resuspended in the original volume of Buffer A. The platelet pellet and supernatant can be solubilized

20 by addition of 1/4 volume of 4X SDS-PAGE loading buffer containing 5% β-mercaptoethanol. The samples can then be boiled for 5 minutes.

For immunoprecipitation, isolated platelets can be either kept at room temperature or chilled and rewarmed. Enzymatic galactosylation transfer can be done as described herein, after which the platelets can be lysed by the addition of

25 0.5 volume of 3X lysis buffer (3% Nonidet P-40, 150 mM Tris/HCl (pH 7.4), 450 mM NaCl, 3 mM EGTA, 3 mM PMSF, 3 mM Na₃VO₄, 30 µg/ml leupeptin and 30 µg/ml aprotinin) (Falet et al., *FEBS Lett.*, 383:165 (1996)). Insoluble material can be removed by centrifugation at 14,000 x g for 10 minutes and the soluble fraction can be immunoprecipitated with 5 µg/ml monoclonal anti-GPIbα antibody WM23

30 bound to protein G-sepharose beads (Pharmacia). Immune complexes can be collected and solubilized in SDS-PAGE buffer containing 5% β-mercaptoethanol.

Proteins can be displayed by SDS-PAGE on an 8% polyacrylamide gel and transferred onto Immobilin-P membrane (Millipore). Membranes can be blocked with 1% BSA in 100 mM NaCl, 20 mM Tris/HCl (pH 7.4) and probed with 5 µg/ml SZ2 or WM23 of the anti-human-GPIb α antibodies followed by the appropriate peroxidase-tagged secondary antibodies or 1 µg/ml peroxidase conjugated-WGA or 0.4 µg/ml RCA-I. Detection can be performed with an enhanced chemiluminescence system (Pierce, Rockford, IL).

Aggregation of platelets can be assessed. Platelets that were chilled, galactosylated or not, or maintained at room temperature, can be washed once with Buffer B by centrifugation and resuspended in Buffer A. Samples of 0.3 ml of platelets can be stirred and exposed to 0.01, 0.1, and 1 U/ml thrombin or 0.06, 0.6, and 6 µg/ml collagen related peptide (CRP) at 37°C. In agglutination experiments, the washed platelets can be treated with UDP-Gal as described above, collected by centrifugation at 300 x g for 5 minutes, resuspended in 0.3 ml of plasma, and exposed to 0.01, 0.1, and 1 mg/ml ristocetin at 37°C. For longterm storage, 0.3 ml samples can be removed at day 0, 1, 2, and 12 from untreated samples and samples treated with UDP-Gal. The samples can be rewarmed to 37°C for 15 minutes and 1 U/ml of thrombin can be added to start the aggregation reaction. Light transmission can be recorded to determine aggregation (Bio/Data aggregometer, Horsham, PA).

Rabbit red blood cell (rRBC) phagocytosis assay. Rabbit blood can be collected into EDTA containing vacutainers (Beckton Dickinson Vacutainer Systems, Franklin Lakes, NJ). rRBCs can be collected by centrifugation at 300 x g, washed 3 times by centrifugation at room temperature with HBSS containing Ca⁺² and Mg⁺² (Gibco Invitrogen) and resuspended in the same buffer at 10⁸ cells / ml in the presence or absence of 10 mM GlcNAc or 10 µM BGlcNAc. Galactose transfer can be performed by addition of 200 or 400 µM UDP-Gal with or without adding 20 mU bovine β 4GalT1 per 10⁸ rRBCs. S-WGA and RCA-I lectin binding can be performed by adding 0.1 µg/ml lectin per 10⁷ rRBCs for 20 minutes at room temperature and using flow cytometry. rRBCs can be preloaded with 5 µM CMFDA as described for platelets and added to the isolated human polymorphonuclear cells (Valerius et al., *Cell*, 24:195 (1981)). 100 µl of rRBCs can

be added to 100 μ l (10^7 cells / ml) polymorphonuclear cells and the cell suspensions can be gently rocked for 30 minutes at 37°C. Adherent rRBCs can be lysed by addition of 10 volumes of H₂O followed by the immediate addition of sufficient 20X saline to return the osmolarity to normal. The neutrophils can be checked for 5 associated rabbit RBCs by light microscopy, stained with a CD11b-PE labeled antibody for 20 minutes on ice, and analyzed by flow cytometry. CD11b positive cells can be gated and 10,000 events acquired.

All publications, patents and patent applications are incorporated herein by reference. While in the foregoing specification this invention has been described in 10 relation to certain preferred embodiments thereof, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details described herein may be varied considerably without departing from the basic principles of the invention.

15 The following statements of the invention are intended to characterize possible elements of the invention according to the foregoing description given in the specification. It is expected that the statements will become claims upon filing a complete U.S. utility application or foreign application claiming priority to the present provisional application. Changes may also be made upon preparation and 20 filing of the complete application. Such changes are not intended to affect the scope of equivalents according to the claims issuing from the complete application, if such changes occur. According to 35 U.S.C. § 111(b), claims are not required for a provisional application. Consequently, statements of the invention are given herein. In addition to statements of the invention, this provisional patent application 25 contains one formal claim that at least should be considered a claim for purposes of filing the application in foreign patent offices.

Formal claim

1. A purified and isolated bovine β (1,4)-galactosyltransferase I wherein methionine is exchanged for histidine at amino acid position 344.

Statements of the Invention

1. A purified and isolated catalytic domain from a β (1,4)-galactosyltransferase I that catalyzes formation of a galactose– β (1,4)-N-acetylglucosamine bond in the presence of magnesium.
2. The catalytic domain according to statement 1, wherein the catalytic domain catalyzes formation of a galactose– β (1,4)-N-acetylglucosamine bond in the presence of any metal.
3. The catalytic domain according to statement 1, wherein the rate of formation of the galactose– β (1,4)-N-acetylglucosamine bond is at least two-fold, five-fold, ten-fold, or one hundred-fold greater than wild-type β (1,4)-galactosyltransferase I in the presence of magnesium.
4. The catalytic domain according to statement 1, wherein the catalytic domain has a conservative amino acid exchange at an amino acid position corresponding to amino acid position 344 of SEQ ID NO: 6.
5. The catalytic domain according to statement 4, wherein histidine is exchanged for methionine at an amino acid position corresponding to amino acid position 344 of SEQ ID NO: 6.
6. The catalytic domain according to statement 1, further comprising a conservative amino acid substitution at an amino acid position corresponding to amino acid position 342 of SEQ ID NO: 6.

7. The catalytic domain according to statement 6, wherein threonine is exchanged for cysteine at amino acid position 342.
8. A polypeptide comprising the catalytic domain according to statement 1.
9. A purified and isolated catalytic domain from a β (1,4)-galactosyltransferase I that catalyzes formation of a glucose– β (1,4)-N-acetylglucosamine bond in the presence of magnesium.
10. The catalytic domain according to statement 9, wherein the catalytic domain catalyzes formation of a glucose– β (1,4)-N-acetylglucosamine bond in the presence of any metal.
11. The catalytic domain according to statement 9, wherein the rate of formation of the glucose– β (1,4)-N-acetylglucosamine bond is at least two-fold, five-fold, ten-fold, or one hundred-fold greater than wild-type β (1,4)-galactosyltransferase I in the presence of magnesium.
12. The catalytic domain according to statement 9, wherein
 - (a) the catalytic domain has conservative amino acid exchanges at amino acid positions corresponding to amino acid positions 344 and 228 of SEQ ID NO: 6;
 - (b) the catalytic domain has conservative amino acid exchanges at amino acid positions corresponding to amino acid positions 344 and 229 of SEQ ID NO: 6; or
 - (c) the catalytic domain has conservative amino acid exchanges at amino acid positions corresponding to amino acid positions 344, 228, and 229 of SEQ ID NO: 6.
13. The catalytic domain according to statement 12, wherein histidine is exchanged for methionine at amino acid position 344, and

(a) lysine is exchanged for arginine at amino acid position 228,
(b) glycine is exchanged for alanine at amino acid position 229, or
(c) lysine is exchanged for arginine at amino acid position 228, and glycine is exchanged for alanine at amino acid position 229.

14. The catalytic domain according to statement 9, further comprising a conservative amino acid substitution at an amino acid corresponding to amino acid position 342 of SEQ ID NO: 6.

15. The catalytic domain according to statement 14, wherein threonine is exchanged for cysteine at amino acid position 342.

16. A polypeptide comprising the catalytic domain according to statement 9.

17. A purified and isolated catalytic domain from a $\beta(1,4)$ -galactosyltransferase I that catalyzes formation of an N-acetylgalactosamine- $\beta(1,4)$ -N-acetylglucosamine bond in the presence of magnesium.

18. The catalytic domain according to statement 17, wherein the catalytic domain catalyzes formation of an N-acetylgalactosamine- $\beta(1,4)$ -N-acetylglucosamine bond in the presence of any metal.

19. The catalytic domain according to statement 17, wherein
(a) the catalytic domain has conservative exchanges of amino acids that correspond to amino acid positions 344 and 289 of SEQ ID NO: 6.

20. The catalytic domain according to statement 17, wherein histidine is exchanged for methionine at an amino acid position that corresponds to amino acid position 344 of SEQ ID NO: 6.

21. The catalytic domain according to statement 19, wherein tyrosine is exchanged for leucine, isoleucine, or asparagine at amino acid position 289.
22. The catalytic domain according to statement 17, further comprising a conservative amino acid substitution at an amino acid position that corresponds to amino acid position 342 of SEQ ID NO: 6.
23. The catalytic domain according to statement 22, wherein threonine is exchanged for cysteine at amino acid position 342.
24. A polypeptide comprising the catalytic domain according to statement 17.
25. A purified and isolated catalytic domain from β (1,4)-galactosyltransferase I that catalyzes formation of an N-acetylgalactosamine– β (1,4)-glucose bond in the presence of α -lactalbumin and magnesium.
26. The catalytic domain according to statement 25, wherein the catalytic domain catalyzes formation of a N-acetylgalactosamine– β (1,4)-glucose bond in the presence of any metal.
27. The catalytic domain according to statement 25, wherein the catalytic domain has conservative amino acid exchanges at amino acid positions that correspond to amino acid positions 344 and 289 of SEQ ID NO: 6.
28. The catalytic domain according to statement 27, wherein histidine is exchanged for methionine at amino acid position 344.
29. The catalytic domain according to statement 27, wherein tyrosine at amino acid position 289 is exchanged with a leucine, isoleucine, or asparagine at amino acid position 289.

30. The catalytic domain according to statement 25, further comprising a conservative amino acid substitution at an amino acid position corresponding to amino acid position 342 in SEQ ID NO: 6.

31. The catalytic domain according to statement 30, wherein threonine is exchanged for cysteine at amino acid position 342.

32. A polypeptide comprising the catalytic domain according to statement 25.

33. A purified and isolated catalytic domain from a β (1,4)-galactosyltransferase I that catalyzes formation of an N-acetylglucosamine– β (1,4)-N-acetylglucosamine bond in the presence of magnesium.

34. The catalytic domain according to statement 33, wherein the catalytic domain catalyzes formation of an N-acetylglucosamine– β (1,4)-N-acetylglucosamine bond in the presence of any metal.

35. The catalytic domain of statement 33, wherein

- (a) the catalytic domain has conservative amino acid exchanges at amino acid positions corresponding to amino acid positions 344 and 228 of SEQ ID NO: 6,
- (b) the catalytic domain has conservative amino acid exchanges at amino acid positions corresponding to amino acid positions 344 and 289 of SEQ ID NO: 6, or
- (c) the catalytic domain has conservative amino acid exchanges at amino acid positions corresponding to amino acid positions 344, 228, and 289 of SEQ ID NO: 6.

36. The catalytic domain of statement 35, wherein

- (a) lysine is exchanged for arginine at amino acid position 228,
- (b) leucine is exchanged for tyrosine at amino acid position 289, or

(c) lysine is exchanged for arginine at amino acid position 228, and leucine is exchanged for tyrosine at amino acid position 289.

37. The catalytic domain according to statement 35, wherein histidine is exchanged for methionine at amino acid position 344.

38. The catalytic domain according to statement 33, further comprising a conservative amino acid substitution at an amino acid position corresponding to amino acid position 342 in SEQ ID NO: 6.

39. The catalytic domain according to statement 38, wherein threonine is exchanged for cysteine at amino acid position 342.

40. A polypeptide comprising the catalytic domain of statement 33.

41. A purified and isolated catalytic domain from a β (1,4)-galactosyltransferase I that catalyzes formation of a mannose- β (1,4)-N-acetylglucosamine bond in the presence of magnesium.

42. The catalytic domain according to statement 41, wherein the catalytic domain catalyzes formation of a mannose- β (1,4)-N-acetylglucosamine bond in the presence of any metal.

43. The catalytic domain according to statement 41, wherein
(a) the catalytic domain has conservative amino acid exchanges at amino acid positions corresponding to amino acid positions 344 and 228 of SEQ ID NO: 6;
(b) the catalytic domain has conservative amino acid exchanges at amino acid positions corresponding to amino acid positions 344 and 289 of SEQ ID NO: 6;
or

(c) the catalytic domain has conservative amino acid exchanges at amino acid positions corresponding to amino acid positions 344, 228, and 289 of SEQ ID NO: 6.

44. The catalytic domain according to statement 43, wherein lysine is exchanged for arginine at amino acid position 228.

45. The catalytic domain according to statement 43, wherein leucine is exchanged for tyrosine at amino acid position 289.

46. The catalytic domain according to statement 41, further comprising a conservative amino acid substitution at an amino acid position corresponding to amino acid position 342 of SEQ ID NO: 6.

47. The catalytic domain according to statement 46, wherein threonine is exchanged for cysteine at amino acid position 342.

48. A polypeptide comprising the catalytic domain according to statement 41.

49. A purified and isolated catalytic domain from a β (1,4)-galactosyltransferase I that catalyzes formation of a galactose- β (1,4)-N-acetylglucosamine-6-SO₃ bond in the presence of magnesium.

50. The catalytic domain according to statement 49, wherein the catalytic domain catalyzes formation of a galactose- β (1,4)-N-acetylglucosamine-6-SO₃ bond in the presence of any metal.

51. The catalytic domain according to statement 49, wherein
(a) the catalytic domain has conservative amino acid exchanges at amino acid positions corresponding to amino acid position 344, 279, and 280 of SEQ ID NO: 6.

52. The catalytic domain according to statement 51, wherein histidine is exchanged for methionine at an amino acid position that corresponds to amino acid position 344 of SEQ ID NO: 6.

53. The catalytic domain according to statement 51, wherein serine is exchanged for lysine at amino acid position 279.

54. The catalytic domain according to statement 51, wherein, and threonine is exchanged for phenylalanine at amino acid position 280.

55. A polypeptide comprising the catalytic domain according to statement 49.

56. A nucleic acid segment encoding a catalytic domain according to any one of statements 1, 9, 17, 25, 33, 41, or 49.

57. An expression cassette comprising the nucleic acid segment according to statement 56.

58. A cell comprising the nucleic acid segment according to statement 56, or the expression cassette according to statement 57.

59. A method to synthesize a galactose- β (1,4)-N-acetylglucosamine moiety comprising incubating a reaction mixture comprising the catalytic domain according to statement 1, with a donor comprising galactose, and an acceptor comprising N-acetylglucosamine.

60. The method according to statement 59, wherein the donor is UDP-galactose and the acceptor is N-acetylglucosamine.

61. An oligosaccharide comprising a galactose- β (1,4)-N-acetylglucosamine moiety synthesized according to the method of statement 59.

62. A method to synthesize a glucose- β (1,4)-N-acetylglucosamine moiety comprising:
incubating a reaction mixture comprising the catalytic domain according to statement 9, with a donor comprising glucose, and an acceptor comprising N-acetylglucosamine.

63. The method according to statement 62, wherein the donor is UDP-glucose, the acceptor is N-acetylglucosamine, or the donor is UDP-glucose and the acceptor is N-acetylglucosamine.

64. An oligosaccharide comprising a glucose- β (1,4)-N-acetylglucosamine moiety synthesized according to the method of statement 62.

65. A method to synthesize an N-acetylgalactosamine- β (1,4)-N-acetylglucosamine moiety comprising:
incubating a reaction mixture comprising the catalytic domain according to statement 17, with a donor comprising N-acetylgalactosamine, and an acceptor comprising N-acetylglucosamine.

66. The method according to statement 65, wherein the donor is UDP-N-acetylgalactosamine, the acceptor is N-acetylglucosamine, or the donor is UDP-N-acetylgalactosamine and the acceptor is N-acetylglucosamine.

67. An oligosaccharide comprising an N-acetylgalactosamine- β (1,4)-N-acetylglucosamine moiety synthesized according to the method of statement 65.

68. A method to synthesize an N-acetylgalactosamine- β (1,4)-glucose moiety comprising incubating a reaction mixture comprising the catalytic domain according

to statement 25, α -lactalbumin, a donor comprising N-acetylgalactosamine, and an acceptor comprising glucose.

69. The method according to statement 68, wherein the donor is UDP-N-acetylgalactosamine, the acceptor is glucose, or the donor is UDP-N-acetylgalactosamine and the acceptor is glucose.

70. An oligosaccharide comprising an N-acetylgalactosamine- β (1,4)-glucose moiety synthesized according to the method of statement 68.

71. A method to synthesize an N-acetylglucosamine- β (1,4)-N-acetylglucosamine moiety comprising incubating a reaction mixture comprising a catalytic domain according to statement 33, with a donor comprising N-acetylglucosamine, and an acceptor comprising N-acetylglucosamine.

72. The method according to statement 71, wherein the donor is UDP-N-acetylglucosamine, the acceptor is N-acetylglucosamine, or the donor is UDP-N-acetylglucosamine and the acceptor is N-acetylglucosamine.

73. An oligosaccharide comprising an N-acetylglucosamine- β (1,4)-N-acetylglucosamine moiety synthesized according to the method of statement 71.

74. A method to synthesize a mannose- β (1,4)-N-acetylglucosamine moiety comprising incubating a reaction mixture comprising the catalytic domain according to statement 41, with a donor comprising mannose, and an acceptor comprising N-acetylglucosamine.

75. The method according to statement 74, wherein the donor is UDP-mannose, the acceptor is N-acetylglucosamine, or the donor is UDP-mannose and the acceptor is N-acetylglucosamine.

76. An oligosaccharide comprising a mannose- β (1,4)-N-acetylglucosamine moiety synthesized according to the method of statement 74.

77. A method to synthesize a galactose- β (1,4)-N-acetylglucosamine-6-SO₃ moiety comprising incubating a reaction mixture comprising the catalytic domain according to statement 49, with a donor comprising galactose, and an acceptor comprising N-acetylglucosamine-6-SO₃.

78. The method according to statement 77, wherein the donor is UDP-galactose, the acceptor is N-acetylglucosamine-6-SO₃, or the donor is UDP-galactose and the acceptor is N-acetylglucosamine-6-SO₃.

79. An oligosaccharide comprising a galactose- β (1,4)-N-acetylglucosamine-6-SO₃ moiety synthesized according to the method of statement 77.

80. A method comprising incubating a reaction mixture comprising an antigen having an acceptor, a donor, and the catalytic domain according to any one of statements 1, 9, 17, 25, 33, 41, or 49 under conditions wherein the β (1,4)-galactosyltransferase I catalyzes bond formation between the donor and the acceptor on the antigen and causes an increase in the immunogenicity of the antigen.

81. The method according to statement 80, wherein the donor is selected from the group consisting of UDP-galactose, UDP-mannose, UDP-N-acetylglucosamine, UDP-glucose, GDP-mannose, and UDP-N-acetylgalactosamine.

82. The method according to statement 80, wherein the acceptor is a carbohydrate, a glycoprotein, or a glycolipid.

83. The method according to statement 82, wherein the carbohydrate is selected from the group consisting of a monosaccharide, a disaccharide, an oligosaccharide, and a polysaccharide.

84. The method according to statement 80, wherein the antigen is a vaccine.

85. The method according to statement 80, wherein the antigen is a protein or a glycoprotein.

86. An antigen prepared according to the method of statement 80.

87. A method to prepare a saccharide composition having a defined sequence comprising:
contacting an acceptor with a first donor in the presence of a first catalytic domain to catalyze linkage of the acceptor with the donor to form a first saccharide composition; and
contacting the first saccharide composition with a second donor in the presence of a second catalytic domain to catalyze linkage of the first saccharide composition with the second donor to form a second saccharide composition,
wherein at least the first catalytic domain or the second catalytic domain is a catalytic domain according to any one of statements 1, 9, 17, 25, 33, 41, or 49, and the other first or second glycosyltransferase is selected from the group consisting of a galactosyltransferase, a sialyltransferase, a fucosyltransferase, an N-acetylgalactosaminyltransferase, an N-acetylglicosaminyltransferase, and a glucuronyltransferase.

88. The method according to statement 87, wherein the first donor or the second donor is selected from the group consisting of UDP-galactose, UDP-mannose, UDP-N-acetylglucosamine, UDP-glucose, GDP-mannose, UDP-N-acetylgalactosamine, UDP-glucuronic acid, GDP-Fucose, and CMP-N-acetylneuraminic acid.

89. The method according to statement 87, wherein the acceptor is a carbohydrate, a glycoprotein, or a glycolipid.

90. The method according to statement 89, wherein the carbohydrate is selected from the group consisting of a monosaccharide, a disaccharide, an oligosaccharide, and a polysaccharide.

91. The method according to statement 87, wherein the acceptor is an antigen.

92. The method according to statement 91, wherein the antigen is a vaccine.

93. The method according to statement 91, wherein the antigen is a protein or a glycoprotein.

94. A composition prepared according to the method of statement 87.

95. A kit comprising packaging material, and a polypeptide comprising the catalytic domain of any one of statements 1, 9, 17, 25, 33, 41, or 49.

96. The kit according to statement 95, further comprising a donor.

97. The kit according to statement 96, wherein the donor is selected from the group consisting of UDP-galactose, UDP-mannose, UDP-N-acetylglucosamine, UDP-glucose, GDP-mannose, UDP-N-acetylgalactosamine, UDP-glucuronic acid, GDP-Fucose, and CMP-N-acetylneuraminic acid.

98. A method to link a donor into an acceptor that is attached to a blood platelet comprising

contacting the blood platelet with a donor and at least one catalytic domain according to any one of statements 1, 9, 17, 25, 33, 41, or 49 to form a reaction mixture, and

incubating the reaction mixture under conditions where the catalytic domain catalyzes linkage of the donor to the acceptor.

99. The method according to statement 98 wherein the donor is exogenous UDP-galactose.

100. The method according to statement 98, wherein the donor is selected from the group consisting of UDP-galactose, UDP-mannose, UDP-N-acetylglucosamine, UDP-glucose, GDP-mannose, UDP-N-acetylgalactosamine, UDP-glucuronic acid, GDP-Fucose, and CMP-N-acetylneuraminic acid.

101. The method according to statement 98, wherein the acceptor is a carbohydrate, a glycoprotein, or a glycolipid.

102. The method according to statement 98, wherein the acceptor is N-acetylglucosamine.

Abstract

Disclosed are mutants of galactosyltransferases that can catalyze formation of oligosaccharides in the presence of magnesium; mutants of galactosyltransferases having altered donor and acceptor specificity which can catalyze formation of oligosaccharides in the presence of magnesium; methods and compositions that can be used to synthesize oligosaccharides; methods for increasing the immunogenicity of an antigen; and methods to stabilize platelets.




FIG. 1A

M344E-Gal-T1




FIG. 1B

M344H-Gal-T1




FIG. 1C




FIG. 2A





FIG. 2B

6/11



Gal-T1
FIG. 3A




FIG. 3B

BEST AVAILABLE COPY

7/11




FIG. 4A

BEST AVAILABLE COPY





FIG. 4B

BEST AVAILABLE COPY




FIG. 4C

BEST AVAILABLE COPY

M344H-Gal-T1




FIG. 5

BEST AVAILABLE COPY

11/11



FIG. 6

BEST AVAILABLE COPY

SEQUENCE LISTING

<110> Qasba, Pradman
Boeggeman, Elizabeth
Ramakrishnan, Boopathy
National Institutes of Health

<120> Catalytic Domains Of Beta(1,4)-Galactosyltransferase I Having Altered Metal Ion Specificity

<130> 1662.027PRV

<160> 13

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 6
<212> PRT
<213> Homo sapiens

<400> 1
Cys Arg Met Ile Arg His
1 5

<210> 2
<211> 7
<212> PRT
<213> Homo sapiens

<400> 2
Phe Asn Arg Ala Lys Leu Leu
1 5

<210> 3
<211> 7
<212> PRT
<213> Homo sapiens

<400> 3
Tyr Val Gln Tyr Phe Gly Gly
1 5

<210> 4
<211> 398
<212> PRT
<213> Homo sapiens

<400> 4
Met Arg Leu Arg Glu Pro Leu Leu Ser Arg Ser Ala Ala Met Pro Gly
1 5 10 15
Ala Ser Leu Gln Arg Ala Cys Arg Leu Leu Val Ala Val Cys Ala Leu
20 25 30
His Leu Gly Val Thr Leu Val Tyr Tyr Leu Ala Gly Arg Asp Leu Ser
35 40 45
Arg Leu Pro Gln Leu Val Gly Val Ser Thr Pro Leu Gln Gly Gly Ser
50 55 60
Asn Ser Ala Ala Ala Ile Gly Gln Ser Ser Gly Asp Leu Arg Thr Gly
65 70 75 80
Gly Ala Arg Pro Pro Pro Pro Leu Gly Ala Ser Ser Gln Pro Arg Pro
85 90 95
Gly Gly Asp Ser Ser Pro Val Val Asp Ser Gly Pro Gly Pro Ala Ser
100 105 110

Asn Leu Thr Ser Val Pro Val Pro His Thr Thr Ala Leu Ser Leu Pro
 115 120 125
 Ala Cys Pro Glu Glu Ser Pro Leu Leu Val Gly Pro Met Leu Ile Glu
 130 135 140
 Phe Asn Met Pro Val Asp Leu Glu Leu Val Ala Lys Gln Asn Pro Asn
 145 150 155 160
 Val Lys Met Gly Gly Arg Tyr Ala Pro Arg Asp Cys Val Ser Pro His
 165 170 175
 Lys Val Ala Ile Ile Ile Pro Phe Arg Asn Arg Gln Glu His Leu Lys
 180 185 190
 Tyr Trp Leu Tyr Tyr Leu His Pro Val Leu Gln Arg Gln Gln Leu Asp
 195 200 205
 Tyr Gly Ile Tyr Val Ile Asn Gln Ala Gly Asp Thr Ile Phe Asn Arg
 210 215 220
 Ala Lys Leu Leu Asn Val Gly Phe Gln Glu Ala Leu Lys Asp Tyr Asp
 225 230 235 240
 Tyr Thr Cys Phe Val Phe Ser Asp Val Asp Leu Ile Pro Met Asn Asp
 245 250 255
 His Asn Ala Tyr Arg Cys Phe Ser Gln Pro Arg His Ile Ser Val Ala
 260 265 270
 Met Asp Lys Phe Gly Phe Ser Leu Pro Tyr Val Gln Tyr Phe Gly Gly
 275 280 285
 Val Ser Ala Ser Ser Lys Gln Gln Phe Leu Thr Ile Asn Gly Phe Pro
 290 295 300
 Asn Asn Tyr Trp Gly Trp Gly Gly Glu Asp Asp Asp Ile Phe Asn Arg
 305 310 315 320
 Leu Val Phe Arg Gly Met Ser Ile Ser Arg Pro Asn Ala Val Val Gly
 325 330 335
 Thr Cys Arg Met Ile Arg His Ser Arg Asp Lys Lys Asn Glu Pro Asn
 340 345 350
 Pro Gln Arg Phe Asp Arg Ile Ala His Thr Lys Glu Thr Met Leu Ser
 355 360 365
 Asp Gly Leu Asn Ser Leu Thr Tyr Gln Val Leu Asp Val Gln Arg Tyr
 370 375 380
 Pro Leu Tyr Thr Gln Ile Thr Val Asp Ile Gly Thr Pro Ser
 385 390 395

<210> 5
 <211> 399
 <212> PRT
 <213> Mus musculus

<400> 5
 Met Arg Phe Arg Glu Gln Phe Leu Gly Gly Ser Ala Ala Met Pro Gly
 1 5 10 15
 Ala Thr Leu Gln Arg Ala Cys Arg Leu Leu Val Ala Val Cys Ala Leu
 20 25 30
 His Leu Gly Val Thr Leu Val Tyr Tyr Leu Ser Gly Arg Asp Leu Ser
 35 40 45
 Arg Leu Pro Gln Leu Val Gly Val Ser Ser Thr Leu Gln Gly Gly Thr
 50 55 60
 Asn Gly Ala Ala Ala Ser Lys Gln Pro Pro Gly Glu Gln Arg Pro Arg
 65 70 75 80
 Gly Ala Arg Pro Pro Pro Pro Leu Gly Val Ser Pro Lys Pro Arg Pro
 85 90 95
 Gly Leu Asp Ser Ser Pro Gly Ala Ala Ser Gly Pro Gly Leu Lys Ser
 100 105 110
 Asn Leu Ser Ser Leu Pro Val Pro Thr Thr Gly Leu Leu Ser Leu
 115 120 125
 Pro Ala Cys Pro Glu Glu Ser Pro Leu Leu Val Gly Pro Met Leu Ile
 130 135 140

Asp	Phe	Asn	Ile	Ala	Val	Asp	Leu	Glu	Leu	Leu	Ala	Lys	Lys	Asn	Pro
145						150				155					160
Glu	Ile	Lys	Thr	Gly	Gly	Arg	Tyr	Ser	Pro	Lys	Asp	Cys	Val	Ser	Pro
				165				170						175	
His	Lys	Val	Ala	Ile	Ile	Ile	Pro	Phe	Arg	Asn	Arg	Gln	Glu	His	Leu
				180				185					190		
Lys	Tyr	Trp	Leu	Tyr	Tyr	Leu	His	Pro	Ile	Leu	Gln	Arg	Gln	Gln	Leu
		195				200			205						
Asp	Tyr	Gly	Ile	Tyr	Val	Ile	Asn	Gln	Ala	Gly	Asp	Thr	Met	Phe	Asn
	210				215				220						
Arg	Ala	Lys	Leu	Leu	Asn	Ile	Gly	Phe	Gln	Glu	Ala	Leu	Lys	Asp	Tyr
	225				230				235				240		
Asp	Tyr	Asn	Cys	Phe	Val	Phe	Ser	Asp	Val	Asp	Leu	Ile	Pro	Met	Asp
		245				250			255						
Asp	Arg	Asn	Ala	Tyr	Arg	Cys	Phe	Ser	Gln	Pro	Arg	His	Ile	Ser	Val
		260				265				270					
Ala	Met	Asp	Lys	Phe	Gly	Phe	Ser	Leu	Pro	Tyr	Val	Gln	Tyr	Phe	Gly
	275				280				285						
Gly	Val	Ser	Ala	Leu	Ser	Lys	Gln	Gln	Phe	Leu	Ala	Ile	Asn	Gly	Phe
	290				295				300						
Pro	Asn	Asn	Tyr	Trp	Gly	Trp	Gly	Gly	Glu	Asp	Asp	Asp	Ile	Phe	Asn
	305				310				315				320		
Arg	Leu	Val	His	Lys	Gly	Met	Ser	Ile	Ser	Arg	Pro	Asn	Ala	Val	Val
		325				330				335					
Gly	Arg	Cys	Arg	Met	Ile	Arg	His	Ser	Arg	Asp	Lys	Lys	Asn	Glu	Pro
		340				345				350					
Asn	Pro	Gln	Arg	Phe	Asp	Arg	Ile	Ala	His	Thr	Lys	Glu	Thr	Met	Arg
	355				360				365						
Phe	Asp	Gly	Leu	Asn	Ser	Leu	Thr	Tyr	Lys	Val	Leu	Asp	Val	Gln	Arg
	370				375				380						
Tyr	Pro	Leu	Tyr	Thr	Gln	Ile	Thr	Val	Asp	Ile	Gly	Thr	Pro	Arg	
	385				390				395						

<210> 6
<211> 402
<212> PRT
<213> Bos taurus

<400> 6															
Met	Lys	Phe	Arg	Glu	Pro	Leu	Leu	Gly	Gly	Ser	Ala	Ala	Met	Pro	Gly
1				5				10					15		
Ala	Ser	Leu	Gln	Arg	Ala	Cys	Arg	Leu	Leu	Val	Ala	Val	Cys	Ala	Leu
					20			25				30			
His	Leu	Gly	Val	Thr	Leu	Val	Tyr	Tyr	Leu	Ala	Gly	Arg	Asp	Leu	Arg
				35			40				45				
Arg	Leu	Pro	Gln	Leu	Val	Gly	Val	His	Pro	Pro	Leu	Gln	Gly	Ser	Ser
		50			55				60						
His	Gly	Ala	Ala	Ala	Ile	Gly	Gln	Pro	Ser	Gly	Glu	Leu	Arg	Leu	Arg
	65				70			75				80			
Gly	Val	Ala	Pro	Pro	Pro	Leu	Gln	Asn	Ser	Ser	Lys	Pro	Arg	Ser	
		85				90				95					
Arg	Ala	Pro	Ser	Asn	Leu	Asp	Ala	Tyr	Ser	His	Pro	Gly	Pro	Gly	Pro
		100				105				110					
Gly	Pro	Gly	Ser	Asn	Leu	Thr	Ser	Ala	Pro	Val	Pro	Ser	Thr	Thr	Thr
		115				120				125					
Arg	Ser	Leu	Thr	Ala	Cys	Pro	Glu	Glu	Ser	Pro	Leu	Leu	Val	Gly	Pro
	130				135				140						
Met	Leu	Ile	Glu	Phe	Asn	Ile	Pro	Val	Asp	Leu	Lys	Leu	Ile	Glu	Gln
	145				150				155				160		
Gln	Asn	Pro	Lys	Val	Lys	Leu	Gly	Gly	Arg	Tyr	Thr	Pro	Met	Asp	Cys
		165				170				175					

Ile Ser Pro His Lys Val Ala Ile Ile Leu Phe Arg Asn Arg Gln
 180 185 190
 Glu His Leu Lys Tyr Trp Leu Tyr Tyr Leu His Pro Met Val Gln Arg
 195 200 205
 Gln Gln Leu Asp Tyr Gly Ile Tyr Val Ile Asn Gln Ala Gly Glu Ser
 210 215 220
 Met Phe Asn Arg Ala Lys Leu Leu Asn Val Gly Phe Lys Glu Ala Leu
 225 230 235 240
 Lys Asp Tyr Asp Tyr Asn Cys Phe Val Phe Ser Asp Val Asp Leu Ile
 245 250 255
 Pro Met Asn Asp His Asn Thr Tyr Arg Cys Phe Ser Gln Pro Arg His
 260 265 270
 Ile Ser Val Ala Met Asp Lys Phe Gly Phe Ser Leu Pro Tyr Val Gln
 275 280 285
 Tyr Phe Gly Gly Val Ser Ala Leu Ser Lys Gln Gln Phe Leu Ser Ile
 290 295 300
 Asn Gly Phe Pro Asn Asn Tyr Trp Gly Trp Gly Gly Glu Asp Asp Asp
 305 310 315 320
 Ile Tyr Asn Arg Leu Ala Phe Arg Gly Met Ser Val Ser Arg Pro Asn
 325 330 335
 Ala Val Ile Gly Lys Cys Arg Met Ile Arg His Ser Arg Asp Lys Lys
 340 345 350
 Asn Glu Pro Asn Pro Gln Arg Phe Asp Arg Ile Ala His Thr Lys Glu
 355 360 365
 Thr Met Leu Ser Asp Gly Leu Asn Ser Leu Thr Tyr Met Val Leu Glu
 370 375 380
 Val Gln Arg Tyr Pro Leu Tyr Thr Lys Ile Thr Val Asp Ile Gly Thr
 385 390 395 400
 Pro Ser

<210> 7
 <211> 113
 <212> PRT
 <213> Homo sapiens

<400> 7
 Arg Asp Leu Ser Arg Leu Pro Gln Leu Val Gly Val Ser Thr Pro Leu
 1 5 10 15
 Gln Gly Gly Ser Asn Ser Ala Ala Ile Gly Gln Ser Ser Gly Asp
 20 25 30
 Leu Arg Thr Gly Gly Ala Arg Pro Pro Pro Pro Leu Gly Ala Ser Ser
 35 40 45
 Gln Pro Arg Pro Gly Gly Asp Ser Ser Pro Val Val Asp Ser Gly Pro
 50 55 60
 Gly Pro Ala Ser Asn Leu Thr Ser Val Pro Val Pro His Thr Thr Ala
 65 70 75 80
 Leu Ser Leu Pro Ala Cys Pro Glu Glu Ser Pro Leu Leu Val Gly Pro
 85 90 95
 Met Leu Ile Glu Phe Asn Met Pro Val Asp Leu Glu Leu Val Ala Lys
 100 105 110
 Gln

<210> 8
 <211> 85
 <212> PRT
 <213> Bos taurus

<400> 8
 Arg Asp Leu Arg Arg Leu Pro Gln Leu Val Gly Val His Pro Pro Leu
 1 5 10 15

Gln	Gly	Ser	Ser	His	Gly	Ala	Ala	Ala	Ile	Gly	Gln	Pro	Ser	Gly	Glu
						20				25				30	
Leu	Arg	Leu	Arg	Gly	Val	Ala	Pro	Pro	Pro	Leu	Gln	Asn	Ser	Ser	
						35			40				45		
Lys	Pro	Arg	Ser	Arg	Ala	Pro	Ser	Asn	Leu	Asp	Ala	Tyr	Ser	His	Pro
						50			55			60			
Gly	Pro	Gly	Pro	Gly	Pro	Gly	Ser	Asn	Leu	Thr	Ser	Ala	Pro	Val	Pro
						65			70			75			80
Ser	Thr	Thr	Thr	Arg											
						85									

<210> 9
<211> 273
<212> PRT
<213> Homo sapiens

<400> 9															
Ser	Leu	Pro	Ala	Cys	Pro	Glu	Glu	Ser	Pro	Leu	Leu	Val	Gly	Pro	Met
						1				5		10			15
Leu	Ile	Glu	Phe	Asn	Met	Pro	Val	Asp	Leu	Glu	Leu	Val	Ala	Lys	Gln
						20				25			30		
Asn	Pro	Asn	Val	Lys	Met	Gly	Gly	Arg	Tyr	Ala	Pro	Arg	Asp	Cys	Val
						35			40			45			
Ser	Pro	His	Lys	Val	Ala	Ile	Ile	Ile	Pro	Phe	Arg	Asn	Arg	Gln	Glu
						50			55			60			
His	Leu	Lys	Tyr	Trp	Leu	Tyr	Tyr	Leu	His	Pro	Val	Leu	Gln	Arg	Gln
						65			70			75			80
Gln	Leu	Asp	Tyr	Gly	Ile	Tyr	Val	Ile	Asn	Gln	Ala	Gly	Asp	Thr	Ile
						85			90			95			
Phe	Asn	Arg	Ala	Lys	Leu	Leu	Asn	Val	Gly	Phe	Gln	Glu	Ala	Leu	Lys
						100			105			110			
Asp	Tyr	Asp	Tyr	Thr	Cys	Phe	Val	Phe	Ser	Asp	Val	Asp	Leu	Ile	Pro
						115			120			125			
Met	Asn	Asp	His	Asn	Ala	Tyr	Arg	Cys	Phe	Ser	Gln	Pro	Arg	His	Ile
						130			135			140			
Ser	Val	Ala	Met	Asp	Lys	Phe	Gly	Phe	Ser	Leu	Pro	Tyr	Val	Gln	Tyr
						145			150			155			160
Phe	Gly	Gly	Val	Ser	Ala	Ser	Ser	Lys	Gln	Gln	Phe	Leu	Thr	Ile	Asn
						165			170			175			
Gly	Phe	Pro	Asn	Asn	Tyr	Trp	Gly	Trp	Gly	Gly	Glu	Asp	Asp	Asp	Ile
						180			185			190			
Phe	Asn	Arg	Leu	Val	Phe	Arg	Gly	Met	Ser	Ile	Ser	Arg	Pro	Asn	Ala
						195			200			205			
Val	Val	Gly	Thr	Cys	Arg	Met	Ile	Arg	His	Ser	Arg	Asp	Lys	Lys	Asn
						210			215			220			
Glu	Pro	Asn	Pro	Gln	Arg	Phe	Asp	Arg	Ile	Ala	His	Thr	Lys	Glu	Thr
						225			230			235			240
Met	Leu	Ser	Asp	Gly	Leu	Asn	Ser	Leu	Thr	Tyr	Gln	Val	Leu	Asp	Val
						245			250			255			
Gln	Arg	Tyr	Pro	Leu	Tyr	Thr	Gln	Ile	Thr	Val	Asp	Ile	Gly	Thr	Pro
						260			265			270			
Ser															

<210> 10
<211> 273
<212> PRT
<213> Bos taurus

<400> 10															
Ser	Leu	Thr	Ala	Cys	Pro	Glu	Glu	Ser	Pro	Leu	Leu	Val	Gly	Pro	Met
						1				5		10			15

<210> 11
<211> 1197
<212> PRT
<213> *Homo sapiens*

```

<400> 11
Ala Thr Gly Ala Gly Gly Cys Thr Thr Cys Gly Gly Gly Ala Gly Cys
      5          10          15
Cys Gly Cys Thr Cys Cys Thr Gly Ala Gly Cys Cys Gly Gly Ala Gly
      20         25         30
Cys Gly Cys Cys Gly Cys Gly Ala Thr Gly Cys Cys Ala Gly Gly Cys
      35         40         45
Gly Cys Gly Thr Cys Cys Cys Thr Ala Cys Ala Gly Cys Gly Gly Gly
      50         55         60
Cys Cys Thr Gly Cys Cys Gly Cys Cys Thr Gly Cys Thr Cys Gly Thr
      65         70         75         80
Gly Gly Cys Cys Gly Thr Cys Thr Gly Cys Gly Cys Thr Cys Thr Gly
      85         90         95
Cys Ala Cys Cys Thr Thr Gly Gly Cys Gly Thr Cys Ala Cys Cys Cys
      100        105        110
Thr Cys Gly Thr Thr Thr Ala Cys Thr Ala Cys Cys Thr Gly Gly Cys
      115        120        125
Thr Gly Gly Cys Cys Gly Cys Gly Ala Cys Cys Thr Gly Ala Gly Cys
      130        135        140
Cys Gly Cys Cys Thr Gly Cys Cys Cys Cys Ala Ala Cys Thr Gly Gly
      145        150        155        160

```

Thr Cys Gly Gly Ala Gly Thr Cys Cys Ala Cys Ala Cys Cys
 165 170 175
 Gly Cys Thr Gly Cys Ala Gly Gly Cys Gly Gly Thr Cys Gly
 180 185 190
 Ala Ala Cys Ala Gly Thr Gly Cys Cys Gly Cys Cys Gly Cys Ala
 195 200 205
 Thr Cys Gly Gly Cys Ala Gly Thr Cys Cys Thr Cys Cys Gly Gly
 210 215 220
 Gly Gly Ala Cys Cys Thr Cys Cys Gly Ala Cys Cys Gly Gly Ala
 225 230 235 240
 Gly Gly Gly Cys Cys Cys Gly Gly Cys Cys Gly Cys Cys Gly Cys
 245 250 255
 Cys Thr Cys Cys Thr Cys Thr Ala Gly Gly Cys Gly Cys Cys Thr Cys
 260 265 270
 Cys Thr Cys Cys Cys Ala Gly Cys Cys Gly Cys Cys Cys Gly
 275 280 285
 Gly Gly Thr Gly Gly Cys Gly Ala Cys Thr Cys Cys Ala Gly Cys Cys
 290 295 300
 Cys Ala Gly Thr Cys Gly Thr Gly Gly Ala Thr Thr Cys Thr Gly Gly
 305 310 315 320
 Cys Cys Cys Thr Gly Gly Cys Cys Cys Gly Cys Thr Ala Gly Cys
 325 330 335
 Ala Ala Cys Thr Thr Gly Ala Cys Cys Thr Cys Gly Gly Thr Cys Cys
 340 345 350
 Cys Ala Gly Thr Gly Cys Cys Cys Ala Cys Ala Cys Cys Ala Cys
 355 360 365
 Cys Gly Cys Ala Cys Thr Gly Thr Cys Gly Cys Thr Gly Cys Cys Cys
 370 375 380
 Gly Cys Cys Thr Gly Cys Cys Thr Gly Ala Gly Gly Ala Gly Thr
 385 390 395 400
 Cys Cys Cys Gly Cys Thr Gly Cys Thr Thr Gly Thr Gly Gly Gly
 405 410 415
 Cys Cys Cys Cys Ala Thr Gly Cys Thr Gly Ala Thr Thr Gly Ala Gly
 420 425 430
 Thr Thr Thr Ala Ala Cys Ala Thr Gly Cys Cys Thr Gly Thr Gly Gly
 435 440 445
 Ala Cys Cys Thr Gly Gly Ala Gly Cys Thr Cys Gly Thr Gly Gly Cys
 450 455 460
 Ala Ala Ala Gly Cys Ala Gly Ala Ala Cys Cys Cys Ala Ala Ala Thr
 465 470 475 480
 Gly Thr Gly Ala Ala Gly Ala Thr Gly Gly Cys Gly Gly Cys Cys
 485 490 495
 Gly Cys Thr Ala Thr Gly Cys Cys Cys Cys Ala Gly Gly Gly Ala
 500 505 510
 Cys Thr Gly Cys Gly Thr Cys Thr Cys Thr Cys Cys Thr Cys Ala Cys
 515 520 525
 Ala Ala Gly Gly Thr Gly Gly Cys Cys Ala Thr Cys Ala Thr Cys Ala
 530 535 540
 Thr Thr Cys Cys Ala Thr Thr Cys Cys Gly Cys Ala Ala Cys Cys Gly
 545 550 555 560
 Gly Cys Ala Gly Gly Ala Gly Cys Ala Cys Cys Thr Cys Ala Ala Gly
 565 570 575
 Thr Ala Cys Thr Gly Gly Cys Thr Ala Thr Ala Thr Thr Ala Thr Thr
 580 585 590
 Thr Gly Cys Ala Cys Cys Cys Ala Gly Thr Cys Cys Thr Gly Cys Ala
 595 600 605
 Gly Cys Gly Cys Cys Ala Gly Cys Ala Gly Cys Thr Gly Gly Ala Cys
 610 615 620
 Thr Ala Thr Gly Gly Cys Ala Thr Cys Thr Ala Thr Gly Thr Thr Ala
 625 630 635 640
 Thr Cys Ala Ala Cys Cys Ala Gly Gly Cys Gly Gly Gly Ala Gly Ala
 645 650 655

Cys Ala Cys Thr Ala Thr Thr Cys Ala Ala Thr Cys Gly Thr
 660 665 670
 Gly Cys Thr Ala Ala Gly Cys Thr Cys Cys Thr Cys Ala Ala Thr Gly
 675 680 685
 Thr Thr Gly Gly Cys Thr Thr Cys Ala Ala Gly Ala Ala Gly Cys
 690 695 700
 Cys Thr Thr Gly Ala Ala Gly Ala Cys Thr Ala Thr Gly Ala Cys
 705 710 715 720
 Thr Ala Cys Ala Cys Cys Thr Gly Cys Thr Thr Gly Thr Gly Thr
 725 730 735
 Thr Thr Ala Gly Thr Gly Ala Cys Gly Thr Gly Ala Cys Cys Thr
 740 745 750
 Cys Ala Thr Thr Cys Cys Ala Ala Thr Gly Ala Ala Thr Gly Ala Thr
 755 760 765
 Cys Ala Thr Ala Ala Thr Gly Cys Gly Thr Ala Cys Ala Gly Gly Thr
 770 775 780
 Gly Thr Thr Thr Thr Cys Ala Cys Ala Gly Cys Cys Ala Cys Gly
 785 790 795 800
 Gly Cys Ala Cys Ala Thr Thr Cys Cys Gly Thr Thr Gly Cys Ala
 805 810 815
 Ala Thr Gly Gly Ala Thr Ala Ala Gly Thr Thr Gly Gly Ala Thr
 820 825 830
 Thr Cys Ala Gly Cys Cys Thr Ala Cys Cys Thr Thr Ala Thr Gly Thr
 835 840 845
 Thr Cys Ala Gly Thr Ala Thr Thr Thr Gly Gly Ala Gly Gly Thr
 850 855 860
 Gly Thr Cys Thr Cys Thr Gly Cys Thr Thr Cys Ala Ala Gly Thr Ala
 865 870 875 880
 Ala Ala Cys Ala Ala Cys Ala Gly Thr Thr Cys Thr Ala Ala Cys
 885 890 895
 Cys Ala Thr Cys Ala Ala Thr Gly Gly Ala Thr Thr Thr Cys Cys Thr
 900 905 910
 Ala Ala Thr Ala Ala Thr Thr Ala Thr Thr Gly Gly Gly Cys Thr
 915 920 925
 Gly Gly Gly Ala Gly Gly Ala Gly Ala Ala Gly Ala Thr Gly Ala
 930 935 940
 Thr Gly Ala Cys Ala Thr Thr Thr Thr Ala Ala Cys Ala Gly Ala
 945 950 955 960
 Thr Thr Ala Gly Thr Thr Thr Thr Ala Gly Ala Gly Gly Cys Ala
 965 970 975
 Thr Gly Thr Cys Thr Ala Thr Cys Thr Cys Gly Cys Cys Cys
 980 985 990
 Ala Ala Ala Thr Gly Cys Thr Gly Thr Gly Gly Thr Cys Gly Gly Gly
 995 1000 1005
 Ala Cys Gly Thr Gly Thr Cys Gly Cys Ala Thr Gly Ala Thr Cys Cys
 1010 1015 1020
 Gly Cys Cys Ala Cys Thr Cys Ala Ala Gly Ala Gly Ala Cys Ala Ala
 1025 1030 1035 1040
 Gly Ala Ala Ala Ala Ala Thr Gly Ala Ala Cys Cys Cys Ala Ala Thr
 1045 1050 1055
 Cys Cys Thr Cys Ala Gly Ala Gly Thr Thr Gly Ala Cys Cys
 1060 1065 1070
 Gly Ala Ala Thr Thr Gly Cys Ala Cys Ala Cys Ala Cys Ala Ala Ala
 1075 1080 1085
 Gly Gly Ala Gly Ala Cys Ala Ala Thr Gly Cys Thr Cys Thr Cys Thr
 1090 1095 1100
 Gly Ala Thr Gly Gly Thr Thr Gly Ala Ala Cys Thr Cys Ala Cys
 1105 1110 1115 1120
 Thr Cys Ala Cys Cys Thr Ala Cys Cys Ala Gly Gly Thr Gly Cys Thr
 1125 1130 1135
 Gly Gly Ala Thr Gly Thr Ala Cys Ala Gly Ala Gly Ala Thr Ala Cys
 1140 1145 1150

Cys Cys Ala Thr Thr Gly Thr Ala Thr Ala Cys Cys Cys Ala Ala Ala
1155 1160 1165
Thr Cys Ala Cys Ala Gly Thr Gly Gly Ala Cys Ala Thr Cys Gly Gly
1170 1175 1180
Gly Ala Cys Ala Cys Cys Gly Ala Gly Cys Thr Ala Gly
1185 1190 1195

<210> 12
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> A synthetic primer

<400> 12
atcgggaaga cgcgtaacat ccgccactcg agagac

36

<210> 13
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> A synthetic primer

<400> 13
atcgggaaga cgcgtagat ccgccactcg agagac

36

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/040844

International filing date: 06 December 2004 (06.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US

Number: 60/527,615

Filing date: 05 December 2003 (05.12.2003)

Date of receipt at the International Bureau: 09 February 2005 (09.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse